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Metabolic syndrome defines a cluster of related comorbidities including obesity, Type 2 
diabetes, fatty liver disease, and cardiovascular diseases. Increasingly prevalent in Western 
countries, metabolic syndrome diseases are a major focus of efforts to understand the complex 
genetics that underlie disease risk and severity. Immunoglobulin domain-containing receptor 2 
(ILDR2) is an endoplasmic reticulum transmembrane protein first identified as a candidate genetic 
modifier of diabetes susceptibility in the context of obesity. Obese, leptin-deficient mice with 
hypomorphic Ildr2 expression had hypoinsulinemic hyperglycemia with reduced beta cell mass, 
suggesting that ILDR2 plays a role in maintain beta cell mass and function. Further studies 
proposed a role for ILDR2 in hepatic lipid metabolism as Ildr2 shRNA-mediated knockdown (KD) 
caused hepatic steatosis in mice. The goal of this thesis work is to clarify the role of ILDR2 in 
diabetes and hepatic steatosis in an effort to elucidate the specific mechanism of ILDR2.  
We developed a conditional Ildr2 knockout (KO) allele, enabling tissue-specific ablation 
in mice. Liver-specific and hepatocyte-specific KO mice did not develop hepatic steatosis. 
However, liver-specific KO mice treated with adenoviral Ildr2 shRNA accumulated hepatic 
triglycerides, suggesting off-target effects of the shRNA. Using RNA sequencing and sequence 
alignment, several gene candidates for shRNA off-targeting effect were identified. Future studies 
are proposed to elucidate role(s) of these genes in the previously described phenotype of Ildr2 KD 
mice. I conclude that Ildr2 ablation may contribute to the development of hepatic steatosis, but 
does not play a major role in hepatic lipid metabolism. 
 
 
We also developed beta cell-specific (RIP2-cre) and pancreas-specific (Pdx-cre) Ildr2 KO 
mice and characterized them for diabetic phenotypes. Pancreas-specific KO mice displayed 
impaired glucose tolerance, reduced insulin secretion and decreased calcium signaling in islets. 
These results confirm a role for ILDR2 in islet cell function. Experiments performed in RIP2-cre 
beta cell-specific KO mice were confounded by effects of the Cre construct, prohibiting definitive 
conclusions about the role of ILDR2 in the beta cell. Additionally, because Ildr2 is expressed at 
low levels in beta cells, we propose that ILDR2 may function in islet macrophages. 
Overall, this work defines the metabolic functions of ILDR2, clarifying its role in hepatic 
lipid metabolism, and confirming its role in islet cell function. In addition, I discuss preliminary 
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Chapter 1: Introduction 
 
Diabetes mellitus 
Diabetes mellitus is defined as a disease characterized by chronic hyperglycemia, due to 
insulin insufficiency [1]. Diabetes mellitus is classified into three disease types with different 
underlying causes but the same major symptom of hyperglycemia. Type 1 diabetes mellitus (T1D) 
- caused by autoimmune destruction of insulin-producing beta cells in the pancreas - and maturity 
onset diabetes of the young (MODY) - caused by loss-of-function mutations in specific genes 
responsible for glucose metabolism or insulin synthesis and secretion - account for 5-10% of all 
instances of diabetes mellitus. Greater than 90% of diabetes mellitus is classified as Type 2 (T2D) 
and is caused by failure of beta cells to produce sufficient insulin to meet the consequences of 
resistance of the body’s metabolic organs to insulin action [2]. As the incipient disease progresses, 
increasing amounts of insulin are required to overcome this resistance and to maintain normal 
blood glucose levels. Eventually, beta cells become unable to meet the demand for insulin 
production and undergo apoptosis or dedifferentiation [3]. If left untreated, T2D results in chronic 
hyperglycemia and its complications of neuropathy, kidney disease and blindness. Often 
associated with obesity, T2D increases risk for developing other metabolic disorders such as fatty 
liver disease, hyperlipidemia, hypertension and cardiovascular disease [4]. Together classified as 
Metabolic Syndrome, these co-morbidities along with the complications of T2D have established 
it as a central metabolic disease and major health concern.  
T2D is one of the most prevalent diseases worldwide, affecting 1 in 11 adults, and is 
predicted to become the 7th leading cause of death by the year 2030 (World Health Organization 




T2D is a significant public health burden across the globe. In the US alone, treatment for T2D and 
its complications costs ~$176 billion annually (Center for Disease Control 2014 National Diabetes 
Statistics report, https://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html). As the 
incidence of T2D continues to rise, there is an urgent need to better understand the causes of, and 
to develop treatments for, this disease. 
 There is a close and well-documented association of T2D with Western lifestyles, including 
diets high in refined sugars and fats but low in fiber, sedentary activities, and environmental 
pollutants [5]. However, while environmental factors may contribute to the risk for developing 
diabetes, they are not the sole determinants of disease. T2D also has a strong hereditary and genetic 
component. This is perhaps best illustrated by twin studies in which diabetes concordance between 
monozygotic and dizygotic twins was evaluated [6-8]. Monozygotic twins, who share the same 
genetics, were found to have ~76% concordance for T2D development [8] vs. 10% in dizygotic 
twins [7] who share the same intrauterine and familial environment, but have different genetics. 
Large-scale genetic analyses of individuals and families segregating for T2D have 
contributed to the identification of several disease-associated genetic loci [9-12]. These studies 
have demonstrated repeatedly that genetic risk for T2D is primarily due to common variants with 
small effect size [9, 10]. However, despite the identification of numerous genetic loci [13-18] we 
are still able to attribute only 6-8% of the known T2D genetic risk [10, 12, 19], indicating that 
there are other genes contributing to T2D susceptibility that are yet to be identified.  
 
Identifying T2D susceptibility genes 
In 2008, Dokmanovic-Chouinard and colleagues published a study in which they 




the goal of identifying novel genetic predictors of T2D risk [20]. Obese C57/BL6J (B6) mice are 
resistant to developing diabetes [21] while DBA/2J (DBA) mice are diabetes -susceptible. 
Dokmanovic-Chouinard et al. intercrossed these mouse strains (also segregating for the ob gene) 
and identified a number of diabetes-susceptibility regions in the DBA genome, among which was 
a particularly strong (genetically and statistically) region on Chr. 1q23. Interestingly, this locus 
corresponds a region which in humans has been with associated T2D in several genome-wide 
association and linkage studies [22-24].   
The Chr. 1 region was refined in B6.DBA ob/ob congenic animals to a 1.8Mb interval 
containing ~14 genes. Congenic mice segregating for DBA alleles in this variable interval 
exhibited hypoinsulinemic hyperglycemia and early reduction in beta cell proliferation leading to 
decreased beta cell mass in adults [20]. Expression of genes in the variable region was measured 
in congenic mice segregating for DBA vs. B6 alleles. The novel gene “Lisch-like” (re-named Ildr2) 
was found to display the most consistently decreased expression in DBA vs. B6 alleles in several 
tissues including liver, hypothalamus, islets and skeletal muscle [20]. These analyses strongly 
suggested that loss of Ildr2 expression in DBA congenic mice was responsible for the diabetic 
phenotypes described above, and identified Ildr2 as the likely causative gene in the Chr. 1 locus. 
It should be noted that all congenic mice were studied in the context of either genetic 
(Lepob/ob) or diet-induced obesity. The absence of extreme obesity and/or leptin deficiency in later 
knockdown (KD) and knockout (KO) mouse models may explain some of the phenotypic 






Immunoglobulin-like domain containing receptor (ILDR) family – structure and function 
The first published reference to Ildr2 describes the human homologue, C1orf32, identified 
in human retina in a screen for alternative transcriptional start sites in highly-expressed retinal 
genes [25]. The mouse Ildr2 gene contains 10 exons which are alternatively spliced to produce 7 
known isoforms [20, 26]. Isoform 1 is the full-length protein; isoforms 3 and 7 do not have a 
transmembrane domain, thus may function as cytosolic or secreted proteins. While Ildr2 is 
ubiquitously expressed, specific isoforms predominate in different tissues. For example, isoform 
2 is highly expressed in the brain, with low expression of isoform 4. Conversely, in the liver 
isoform 4 has much higher expression than isoform 2. Exons 1, 2, 3 and 10 are present in all known 
ILDR2 isoforms [26]. 
ILDR2 is a member of the immunoglobulin-like domain containing receptor (ILDR) 
family. Classified by structural similarity only, ILDR1/2/3 are Type 1 transmembrane receptor-
like proteins with N-terminal immunoglobulin (IgG)-like domains, helical transmembrane 
domains, and C-terminal “tails” containing several putative signaling elements and binding sites 
[20]. 
ILDR3, also known as lipolysis-stimulated receptor (LSR), was the earliest identified 
ILDR family member. ILDR3 is a nominal lipoprotein remnant receptor activated by free fatty 
acids (FFAs) in the liver [27], and ILDR3-deficient mice exhibit hyperlipidemia consistent with 
decreased hepatic lipoprotein uptake [28, 29]. ILDR3 is also important for recruiting tricellulin for 
the formation of epithelial and endothelial tricellular tight junctions (tTJs) [30-32]. ILDR3 
regulates cholesterol distribution in the brain [33] and may link cholesterol levels to amyloid stress 
in Alzheimer’s disease [34]. ILDR3 also plays a role in blood-brain barrier (BBB) formation where 




ILDR1 has been implicated in autosomal recessive disorders of deafness in several families 
[36, 37], which has been linked to its function at epithelial tTJs [38]. Ildr1-deficient mice also 
exhibit specific hearing deficits due to loss of tTJ integrity in the inner ear [39-41]. ILDR1 may 
have a similar function in the kidney where tTJs help regulate water permeability [42]. ILDR1 also 
plays a role in sensing intestinal lipid to regulate cholecystokinin (CCK) secretion in the gut [43], 
which appears to be the only described role not linked to its location in tTJs. 
Together, ILDR1/2/3 have recently been termed “angulins” due to their location at 
epithelial tTJs [38]. As described above, ILDR1 and ILDR3 appear to be critical for the integrity 
of tTJs in multiple tissues [32, 35, 41, 42]. However ILDR2 seems to have limited function in this 
capacity [38], which is consistent with previous findings placing ILDR2 at the endoplasmic 
reticulum (ER), rather than at the cellular membrane [26]. 
 
Location of ILDR2 in the endoplasmic reticulum membrane 
ILDR1 and ILDR3 are expressed and localized to the plasma membrane. To determine the 
location of ILDR2 in the cell, fluorescently-labeled Ildr2 was overexpressed in liver (Hepa1c1c7) 
and hypothalamic (GT1-7) cell lines along with markers for either the ER or the plasma membrane. 
Both C-terminal and N-terminal-tagged ILDR2 localized to the ER in both cell types [26], and did 
not change location in response to glucose, insulin, free fatty acids or low-density lipoprotein 
(LDL) in Hepa1c1c7 cells.  
The location of ILDR2 in the ER membrane suggests a number of functional and 
mechanistic roles for this novel protein including regulation of various protein secretory pathways, 
such as lipid synthesis and secretion in the liver or insulin folding and secretion in beta cells, 




pathways. While ILDR2 may localize to the cell membrane in certain cell types or under specific 
conditions [38], further mechanistic studies suggest that its ER location is central to its function in 
metabolic diseases. 
 
The ENU-mutagenized W87* Ildr2-deficient mouse 
Since the identification of Ildr2 as a candidate modifier of diabetes susceptibility, 
numerous attempts have been made to develop systemic and tissue-specific KD and KO models 
of Ildr2. One of the mouse models used to investigate the function of ILDR2 was an ENU-
mutagenized mouse with a stop mutation at tryptophan-87 in the Ildr2 gene sequence [20]. Located 
in exon 2, this mutation should cause severe truncation of Ildr2 mRNA and degradation of any 
translated protein. Indeed, immunoblots of hypothalamic extracts from ENU-mutagenized (W87*) 
mice did not detect any ILDR2 protein [20]. W87* mice on a C3HebFeJ background were analyzed 
for diabetic phenotypes and showed decreases in beta cell replication similar to the B6.DBA 
congenic mice. However, there were only slight differences in insulin: glucose ratios and glucose 
tolerance between W87* and C3HebFeJ wild-type (WT) mice [20]. Additionally, 2D 
polyacrylamide gel (2D-PAGE) analysis of W87* hypothalamic and liver proteins revealed that 
several calcium binding and regulatory proteins were decreased in W87* mice, and suggested a 
role for ILDR2 in calcium homeostasis. 
As described above, ILDR3 has been well-characterized as a lipoprotein receptor in the 
liver and Ildr3-deficient mice have defects in lipid homeostasis [29]. Hypothesizing that ILDR2 
might be similarly involved in lipid metabolism, W87* mice were further characterized for 
additional metabolic phenotypes related to obesity and lipid metabolism. Low-fat chow fed W87* 




refed blood glucose levels. Serum cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) were also elevated in W87* mice. Hepatic triglyceride and cholesterol esters 
were slightly increased in W87* mice, but chylomicron clearance and hepatic VLDL secretion 
were unchanged in W87* vs. WT mice. These data suggested that lipid metabolism was 
dysregulated in W87* mice, but when hepatic Ildr2 expression was measured, there was no 
difference in expression between W87* and WT mice. Further analyses revealed that some full-
length Ildr2 expression was retained in W87* mice, indicating that the stop mutation was not 
completely penetrant, and W87* mice were not true KOs. 
 
The adenoviral-shRNA Ildr2 KD mouse 
 Another Ildr2-deficient mouse was developed using an Ildr2 short-hairpin RNA (shRNA). 
This shRNA was targeted again to exon 2 of the Ildr2 gene sequence and cloned into an adenoviral 
construct [26]. Unlike the B6.DBA congenics or W87* mice, this KD model had a tissue-specific 
limitation in that adenovirus targets the liver almost exclusively. Aside from the liver phenotypes 
of W87* mice, which were shown to retain some Ildr2 expression, there was no evidence that 
ILDR2 played any role in the liver. However, adenoviral-shRNA provided a way to investigate 
the mechanism of this novel gene in an in vivo setting. 
 Ildr2-shRNA adenovirus or a control lacZ-shRNA adenovirus were administered to 10-
week-old B6 mice, which were then euthanized 3, 7, or 10 days post adenovirus infection. While 
major changes were not apparent after 3 days, by 7 days mice developed gross hepatic lipid 
accumulation which was even more striking at 10 days post adenovirus infection [26]. This hepatic 
steatosis was accompanied by hyperlipidemia, an HDL to VLDL shift in plasma lipoproteins, and 




that at 3 days post-infection lipogenic genes were upregulated in livers of Ildr2-shRNA 
adenovirus-infected (ADKD) mice vs. controls, but by 10 days lipogenic genes were 
downregulated in ADKD mice [26]. These data suggested that lipogenesis is the primary pathway 
affected by Ildr2 KD, and the steatosis observed at 10 days was the result of uncontrolled 
lipogenesis occurring at or around 3 days post-infection. Lipid synthesis genes might then have 
been downregulated at 10 days in response to excess lipid accumulation. 
 WT mice were also treated with adenoviruses over-expressing Ildr2 or Gfp as a control. 
Ildr2 overexpression (ADOX) had the opposite effect of KD, reducing hepatic lipid content in 
ADOX mice vs. controls [26]. Gene expression analysis revealed similar broad changes in lipid 
metabolic transcripts. However, in OX mice these genes were downregulated at 3 days post 
infection, and upregulated at 10 days after adenovirus administration. The converse changes in 
gene expression between these two time-points, as well as between ADKD vs. ADOX models 
suggests that lipogenic genes are tightly regulated to maintain a homeostatic balance and control 
hepatic lipid content.  
Separate groups of C57BL/6J Lepob/ob were included in both the KD and OX arms of these 
experiments. In both cases the phenotypes were consistent with results in WT mice. By 10 weeks 
of age Lepob/ob mice had developed fatty liver, thus ADKD exacerbated their phenotype, while 
ADOX ameliorated the hepatic steatosis of Lepob/ob mice [26].  
Additional Ildr2 overexpression experiments were performed in high-fat, high-fructose 
diet (HFHFD)-fed wild-type mice. Mice infected with ADOX for 10 days showed no difference 
in hepatic lipid content vs. control-infected mice. However, this may have been due to extensive 
fibrosis in the livers of HFHFD mice, which was absent in Lepob/ob mice. Ildr2 OX restored the 




- Perk, eif2a, and Atf4 - were increased in ADOX mice, although activation (phosphorylation) of 
PERK and eIF2α was unchanged in ADOX mice vs. controls. In the aggregate, these Ildr2 KD 
and OX experiments suggested that ILDR2 played a key role in the regulation of hepatic lipid 
metabolism.  
 
Transcriptional regulation of Ildr2 by USF1 and ER stress modulators 
In addition to establishing Ildr2-deficient mouse models, efforts were also made to 
understand the molecular function of ILDR2 and to analyze how it modifies diabetes susceptibility. 
These studies were necessarily informed by the fatty liver phenotype of Ildr2 ADKD mice and a 
desire to elucidate the mechanism of ILDR2 with respect to its putative role in hepatic lipid 
homeostasis.  
In ADKD and ADOX mice, in addition to changes in lipid metabolic transcripts, several 
genes involved in the UPR were differentially regulated. Gene expression changes did not reflect 
a specific pattern of up- or down-regulation related to Ildr2 KD or OX, but did suggest that these 
pathways were affected by Ildr2 manipulation [26]. These results correlate with in vitro 
experiments in neuronal (GT1-7) and beta (BTC-6) cell lines as well as primary hepatocytes. Ildr2 
was knocked down for 48 hours via siRNA (GT1-7 and BTC-6) or adenoviral-shRNA (primary 
hepatocytes) and UPR genes were measured by quantitative PCR. Several genes were significantly 
up- or down-regulated as a result of Ildr2 KD, but similar to the in vivo results, no clear pattern 
was observed to confirm activation or rescue of ER stress in the context of Ildr2 KD. 
To understand how Ildr2 may be regulated by ER stress-related transcription factors, 
human and mouse Ildr2 promoter regions were analyzed for putative transcription factor binding 




in the human ILDR2 promoter. Electro-mobility shift assays (EMSA) and luciferase assays 
confirmed that the transcription factor – upstream stimulatory factor 1 (USF1) – binds to the Ildr2 
promoter, activating its transcription. USF1 is a transcription factor that regulates several 
metabolic genes by binding E-box motifs in the promoter region of these genes [44-46]. Ildr2 is 
upregulated by glucose treatment in HepG2 (human hepatoma) cell in a USF1-dependent manner. 
It has also been shown that Ildr2 expression is increased in the livers of Lepob/ob and HFD-fed mice 
compared to WT mice, but it is not known if this increase is USF1-dependent. In shRNA-mediated 
USF1 KD mice, Ildr2 was decreased by 40% and hepatic triglyceride (TG) was increased 1.5-fold 
3 days post-KD, but not as strikingly as seen in ADKD mice described earlier. These studies 
suggested that USF1 was probably not the single primary mechanism by which Ildr2’s action on 
lipid metabolism could be mediated.  
DNA sequence comparisons between the human ILDR2 promoter and the mouse Bip 
promoter revealed E-box and ERSE motifs in both. It was hypothesized that UPR transcription 
factors activating transcription factor 6 (ATF6) and X-box binding protein 1 (XBP1) which 
activate Bip might also bind the Ildr2 promoter. This hypothesis was confirmed by EMSA and 
chromatin immunoprecipitation (ChIP) experiments, but measurement of Ildr2 expression upon 
overexpression of ATF6 and XBP1 showed that these transcription factors suppress, rather than 
activate Ildr2 expression. Further analysis of the transcription factor binding site revealed that the 
close alignment between the E-box and ERSE regions of the Ildr2 promoter introduced physical 
constraints to USF1 and ATF6/XBP1 binding simultaneously. It is likely that competition between 
USF1 and ATF6/XBP1 determine which transcription factors bind and, consequentially, activate 
or inhibit Ildr2. This competitive binding could be a key aspect of how Ildr2 expression is 




Additional regulation of ILDR2 by UPR modulators was elucidated in co-
immunoprecipitation experiments performed to identify novel binding interactions. Co-
immunoprecipitation of ILDR2 and protein kinase R (PKR)-like ER kinase (PERK), an ER stress 
transducer, revealed ILDR2 cleavage products in PERK over-expressing cells. Since PERK has 
no known protease activity, the presence of these cleavage products suggests that ILDR2 is subject 
to protease degradation downstream of PERK, although whether the ILDR2 fragments are 
biologically active or, simply become substrates for proteosomal degradation, is unknown.  
Co-immunoprecipitation of ILDR2 and inositol-requiring enzyme 1 (IRE1), the ER stress 
transducer of a second UPR pathway, resulted in complete degradation of Ildr2 mRNA. Co-
transfection with IRE1 mutants revealed that the endoribonuclease, but not the kinase, activity of 
IRE1 is required to degrade Ildr2 transcript, suggesting that Ildr2 may be a target of regulated 
IRE1-dependent decay (RIDD). RIDD describes a quality control mechanism in which IRE1 
targets and degrades select mRNA transcripts [47]. RIDD appears to be activated separately from 
the UPR [48], and may be a parallel mechanism to decrease ER protein load. So et al. have shown 
that in states of excess lipid accumulation, RIDD may be activated to specifically degrade 
lipogenic transcripts and restore lipid homeostasis [49]. Additional studies indicated that Ildr2 is 
down-regulated by chemical induction of ER stress both in vivo and in vitro, consistent with the 
results described above. 
Taken together these studies highlight multiple pathways for modulating Ildr2 expression 
at both the transcriptional and translational levels. Given its location in the ER membrane, ILDR2 
may directly interact with ER stress transducers, but it appears to be regulated downstream of 
canonical ER stress molecules. If ER stress is a consequence of Ildr2 manipulation, it would occur 




ILDR2 specifically binds Apolipoprotein E 
The ER localization of ILDR2 and the phenotype of Ildr2 ADKD mice suggest that ILDR2 
may be involved in lipid synthesis and secretion. Co-immunoprecipitation with various 
apolipoproteins showed that ILDR2 binds ApoE, but not ApoA, ApoB, or ApoC. ApoE 
specifically bound to a region in exon 7 of the ILDR2 amino acid sequence that has close similarity 
to the known binding site of ApoE in the amyloid beta protein [50]. Hypotheses can be made about 
the function of ILDR2-ApoE binding, e.g. ILDR2 may help to stabilize nascent lipoprotein 
particles in the ER. One part of the proposed mechanism that does not fit, however, is that exon 7 
is in the C-terminal portion of ILDR2 which is predicted to be cytoplasmic, not lumenal. This 
orientation may suggest that ILDR2 interacts with ApoE in endosomes, helping to recycle ApoE 
through the endosomal pathway. Studies placing ILDR2 at the plasma membrane [38] may help 
explain the interaction of ILDR2 and ApoE, although the structurally-similar lipoprotein receptor, 
ILDR3, is thought to bind lipoproteins at its IgG-like domain. 
 
ILDR2 interacts with ZNF70, a modulator of Notch signaling 
 In a tandem affinity purification screen to identify novel ILDR2 binding proteins ZNF70, 
a Kruppel C2H2-type zinc finger protein, was identified [51].  ZNF70 interacts with ZNF64 [52], 
a related zinc transcription factor and regulator of Notch signaling [53]. Ildr2 shRNA KD in 
HEK293 cells resulted in nuclear translocation of ZNF70 and upregulation of Hes1, a canonical 
Notch target gene and transducer of Notch signaling [51]. This study suggests that ILDR2 may 
play a role in regulating Notch signaling pathways. Initially described as an essential 




signaling pathways as well [55, 56]. A link between ILDR2 and Notch signaling could account for 
ILDR2’s putative roles in both hepatic lipid metabolism and diabetes development. 
 
Summary and overview of chapters 
        Ildr2 was first identified as a candidate modifier of T2D in Lepob/ob mice in which reduced 
Ildr2 expression was associated with hypoinsulinemic hyperglycemia and other diabetic 
phenotypes [20]. The primary positioning of ILDR2 in the ER membrane [26] suggests that it 
might be involved in protein synthesis and secretion, calcium homeostasis or ER stress signaling, 
although ILDR2 has also been localized to the cell membrane and hypothesized to have a putative 
role in tight junction biology [38]. Ildr2-deficient mouse models have implicated Ildr2 in lipid 
metabolism, evidenced by the striking hepatic steatosis observed in Ildr2 KD mice, and the rescue 
of steatosis in Lepob/ob mice by Ildr2 overexpression [26]. 
        Several mechanistic experiments have been performed to understand the molecular regulation 
of Ildr2 and identify putative binding partners. These studies have shown that Ildr2 is regulated by 
several UPR factors, binds ApoE, and is involved in modulating Notch signaling [51]. However a 
specific mechanism of ILDR2 that describes its function in modifying diabetes susceptibility or 
regulating lipid metabolism has yet to be elucidated.   
        The goal of my thesis work is to verify the functional role of ILDR2 in the liver and pancreas 
using tissue-specific Ildr2 KO mouse models. Developed using the Cre-loxP system, these KO 
mice provide more specific, complete, and reliable Ildr2 ablation than any of the Ildr2-deficient 
models previously used. 
        In Chapter 2, I describe several liver-specific and hepatocyte-specific Ildr2 KO mice, with 




not recapitulate the fatty liver phenotypes of adenoviral shRNA-mediated Ildr2 KD and do not 
exhibit any apparent metabolic abnormalities. I then show that the adenoviral Ildr2 shRNA itself 
causes hepatic lipid accumulation regardless of Ildr2 expression and suggest that off-target effects 
of the shRNA are responsible for the steatotic phenotype of ADKD mice. Following RNAseq of 
KD and KO liver samples, I propose gene candidates that may have been targeted by the Ildr2 
shRNA, and whose suppression could have contributed to the hepatic steatosis in ADKD mice. 
Experiments in this chapter confirm that ILDR2 does not play a major role in lipid metabolism.  
        In Chapter 3, I develop pancreas-specific and beta cell-specific Ildr2 KO mice, with the goal 
of recapitulating the diabetic phenotype of the original Ildr2-hypomorphic, B6.DBA congenic 
mice and gaining a better understanding of the function of Ildr2 in diabetes. I describe a phenotype 
of impaired glucose tolerance, reduced in vivo insulin secretion, and increased beta cell area in 
beta cell-specific (RIP2-cre) KO mice; while pancreas-specific (Pdx-cre) KO mice display 
impaired glucose tolerance, decreased ex vivo islet insulin secretion and calcium signaling, but 
normal islet morphology. I find that Ildr2 expression is retained in the islets of beta cell-specific 
(RIP2-cre) KO mice, but is completely ablated in pancreas-specific (Pdx-cre) KOs, suggesting that 
expression in non-beta, islet cells is masking the beta cell KO of Ildr2. Expression studies 
indicating that Ildr2 is expressed at low, though detectable, levels in beta cells corroborate this 
hypothesis. Since Ildr2 appears to be expressed at similarly low levels in other islet endocrine 
cells, I hypothesize that islet macrophages could be the source of Ildr2 expression in beta cell-
specific KO mice, particularly as Ildr2 is known to be expressed in liver and adipose tissue 
macrophages. However, confounding effects of the RIP2-cre construct may affect the phenotype 
of beta cell-specific Ildr2 KO mice. I discuss how interpret these data in comparison with pancreas-




         In Chapter 4, I discuss how my work contributes to the general body of knowledge about 
ILDR2 and propose further studies to move this work forward. I revisit the identification of Ildr2 
as a diabetes susceptibility gene in Lepob/ob and suggest that leptin may play a role in the biology 
of Ildr2. The Ildr2-related phenotypes observed in leptin-deficient mice – reduced beta cell mass 
with Ildr2 hypomorphism, and rescue of hepatic steatosis by Ildr2 overexpression – have not been 
replicated in WT mice, even with diet-induced obesity. I also review preliminary data proposing 
that Ildr2 may regulate body mass composition, which could also involve leptin biology. Overall 
my work has clarified which phenotypes and proposed functions are or are not attributable to Ildr2 
expression, and established several mouse models enabling studies of the precise roles of ILDR2 
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Chapter 2: The role of ILDR2 in hepatic lipid metabolism 
 
Introduction 
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the leading cause of liver 
failure and transplantation in the United States and is predicted to affect ~30% of adults in the US 
[1, 2]. Often considered the major liver manifestation of the metabolic syndrome, NAFLD is 
closely associated with obesity, diabetes and insulin resistance [3]. While the simple steatosis that 
defines NAFLD is relatively benign, it can progress to steatohepatitis (known as NASH) with 
inflammatory infiltration and fibrosis [4]. The physiological and metabolic factors that trigger 
progression from NAFLD to NASH remain poorly understood. 
The Ildr2 gene appeared to play a role in the development of NAFLD, possibly through 
mechanisms of endoplasmic reticulum (ER) stress. Initially characterized by positional genetics as 
a diabetes-susceptibility gene in mice [5], Ildr2 knockdown via adenovirally-delivered shRNA 
(ADKD) resulted in gross hepatic steatosis and inflammation within 10 days of infection [6]. Gene 
expression analysis indicated initial upregulation of lipogenic transcripts (3 days post-adenovirus 
infection), followed by downregulation of these transcripts after development of steatosis, as well 
as differential expression of genes involved in the unfolded protein (“ER stress”) response 
pathways [6]. 
In this previous study, we utilized an adenoviral delivery system to target short hairpin 
RNA (shRNA) to the liver in order to produce an acute liver-specific knockdown of Ildr2. In the 
absence (at the time) of any congenital Ildr2 KO mouse models, the Adv-shRNA system allowed 
us to investigate the effects of acute knockdown of Ildr2 transcripts in the liver. However this 
system is imperfect for several reasons: Adv infection is known to trigger inflammation [7-9] 
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which plays a role in the progression of NAFLD and development of NASH [10, 11]; Adv can 
also target other tissues and even though the majority is taken up by the liver [12-14], with potential 
consequences for gene expression in those tissues; and, finally, shRNA itself can have off-target 
effects and reduce expression of genes not intentionally targeted [15, 16].  
Here we describe liver-specific Ildr2 gene deletion models achieved using the Cre-loxP 
system. We discuss the development of liver-specific Ildr2 knockout (KO) mice and further 
characterize them to understand the putative role of Ildr2 in hepatic steatosis. The differing 
phenotypes observed in Ildr2 Adv-shRNA KD vs. KO models highlight some of the pitfalls of 
using adenoviruses and shRNA for genetic manipulations; these are discussed below.  
 
Results 
Congenital, hepatocyte-specific Ildr2 KO mice do not develop hepatic steatosis 
To produce a conditional Ildr2 knockout mouse model, we introduced loxP sites flanking 
exon 1 of the Ildr2 gene (exon 1 is included in all seven known Ildr2 transcript isoforms [5]) to 
create an Ildr2 floxed mouse (Ildr2fl/fl) (Fig. 2.1A). To explore the function of ILDR2 in the liver, 
we crossed Ildr2fl/fl mice with mice expressing Cre recombinase driven by the albumin promoter, 
obtaining hepatocyte-specific, congenital Ildr2 knockout mice (see Table 1 for nomenclature). 
Ildr2 liver mRNA expression was reduced >99% in hepatocyte-specific Ildr2 KO mice (Ildr2Alb 
KO) compared to Ildr2fl/fl littermate controls (Fig. 2.1B). Although a subset of these mice retained 
Ildr2 expression – indicating that the albumin-cre was not completely penetrant – these mice 
displayed no phenotypic differences vs. complete Ildr2Alb KO mice. 
When fed, ad libitum, low-fat (10% kcal as fat) chow diet, male, Ildr2Alb KO mice did not 
differ in body weight and body composition from Ildr2fl/fl littermates (Fig. 2.1C). When fed ad 
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libitum a high-fat diet (HFD, 60% kcal as fat) from 6-23 weeks of age, they increased body weight 
and fat mass in tandem with their Ildr2fl/fl HFD-fed littermates (Fig. 2.1D). 
23-week-old, chow-fed Ildr2Alb KO mice did not exhibit hepatic steatosis by inspection, 
histology, or quantitative chemical analysis (Fig. 2.1E-G). They also had normal plasma 
triglyceride and total cholesterol concentrations (Fig. 2.1H). 23-week-old, HFD-fed mice showed 
hepatic lipid accumulation and elevated plasma lipids, but there was no significant difference 
between Ildr2Alb KO mice and littermate controls fed the same HFD (Fig. 2.1G,H). 
 
Acute, hepatocyte-specific Ildr2 KO mice do not develop hepatic steatosis 
The absence of steatosis in Ildr2Alb KO mice led us to postulate that the congenital nature 
of the KO may have triggered gene compensation for the lack of ILDR2 during development. The 
mouse albumin gene is turned on at ~E10.5, about halfway through embryonic development [17], 
and Cre expression has been detected in fetal mouse hepatocytes from albumin-cre mice as early 
as E14.5, as immature cells begin to differentiate into hepatocytes [18]. Critical genes deleted at 
this stage in development may be functionally compensated by functionally similar [19-21]. 
Compensation for the loss of Ildr2 in Ildr2Alb KO mice could explain the absence of increased 
steatosis in the Ildr2Alb KO mice.  
To address this possibility, we designed a mouse model in which Ildr2 can be acutely 
ablated in the adult animals, similar to the original Adv-shRNA KD mice (ADKD) mice. We 
utilized an adeno-associated virus (AAV) construct incorporating thyroid-binding globulin (TBG) 
promoter-driven Cre or GFP (control). This AAV8-TBG-Cre (developed by the Penn Vector Core) 
enables acute Cre expression specifically in hepatocytes, knocking out Ildr2 (Ildr2AAV KO). We 
injected AAV8-TBG-Cre intravenously into 13-week-old, chow-fed Ildr2fl/fl mice and examined 
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livers 10 days post-injection, in keeping with the timeline of development of steatosis in ADKD 
mice. Despite complete KO of Ildr2 (Fig. 2.2A), livers of Ildr2AAV KO mice were normal, showing 
no steatosis or any lipid metabolic abnormalities when compared to mice injected with the AAV8-
TBG-GFP control construct (Fig. 2.2B,C). To determine the timing of AAV delivery and gene 
interruption, we measured hepatic mRNA expression of Ildr2 isoforms 1 through 5 (only isoform 
1 is shown) in mice at 2, 4, 6, 8, 10 and 12 days post injection and found that Ildr2 transcript 
elimination occurred as early as 2 days post-injection (Fig. 2.2D). We also followed mice for 6 
weeks after AAV infection, measuring plasma lipids at 20 days post-injection, then at 11-day 
intervals until sacrifice. Ildr2AAV KO mice had normal plasma lipid levels and did not exhibit any 
hepatic lipid accumulation or metabolic abnormalities at 6 weeks post-injection with AAV (Fig. 
2.2E-G). 
 
Acute, Adv-mediated, liver-specific Ildr2 KO mice do not develop hepatic steatosis 
Next, we considered the possibility that loss of Ildr2 in non-parenchymal liver cells may 
have contributed significantly to the steatosis observed in our original ADKD mice [6]. Both the 
AAV-TBG-Cre and the albumin-cre were designed to induce recombination and gene knockout 
specifically in hepatocytes. Hepatocytes comprise ~80% of liver tissue. However, the shRNA 
adenovirus used to produce ADKD mice would have targeted additional liver cell types, such as 
liver macrophages (Kupffer cells), stellate cells, and epithelial cells. While hepatic steatosis is 
defined as lipid accumulation in hepatocytes, non-parenchymal liver cells can accelerate the 
progression of steatosis to more advanced liver disease [22-25]. As resident liver macrophages, 
Kupffer cells initiate the immune response to metabolic injury, secreting pro-inflammatory 
chemokines and cytokines such as IL-1β and TNF, stimulating pro-apoptotic signaling pathways 
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in hepatocytes, and recruiting circulating immune cells to the liver [25-27]. Stellate cells play a 
key role in the induction of fibrosis in liver disease, and can transdifferentiate into myofibroblasts 
leading to increased production of collagen and extra-cellular matrix (ECM) factors [24, 27, 28].  
To determine if Ildr2 is expressed in non-parenchymal liver cells, or in hepatocytes only, 
primary hepatocytes and non-parenchymal cells were isolated from 12-week-old mice using liver 
collagenase digestion. Hepatocyte and non-hepatocyte cell fractions were separated by 
centrifugation [29]. Gene expression analysis of liver cell markers was used to confirm the cellular 
identity of each fraction. Tbg, a hepatocyte-specific marker, and F4/80, a macrophage-specific 
marker, were highly expressed in the hepatocyte and non-hepatocyte fractions, respectively (Fig. 
2.3A). Ildr2 was expressed in both cell fractions, although expression in the non-hepatocyte cell 
fraction was about one-third of Ildr2 expression in the hepatocyte cell fraction (Fig. 2.3A). A 
caveat to this experiment is that because these cell fractions were sorted by centrifugation, there 
was some degree of cross-contamination as indicated by low level Tbg expression in the non-
hepatocyte fraction, and F4/80 expression in hepatocyte fraction (Fig. 2.3A). Microarray 
expression data from Xu, et al. also confirms that Ildr2 is expressed in various populations of 
adipose tissue macrophages [30]. Taken together, these results suggest that Ildr2 ablation in non-
parenchymal liver cells could contribute to the steatotic phenotypes of the ADKD mice, and thus 
explain the lack of hepatic steatosis in the acute and chronic transgenic KO mice. 
To address this question, we created another acute Ildr2 KO model by employing an 
adenoviral-Cre construct rather than the AAV-TBG-Cre used previously. While the AAV-TBG-
Cre construct is designed to impact only hepatocytes, adenoviral-Cre targets both parenchymal 
and non-parenchymal liver cells [31, 32]. 11-week-old, male, Ildr2fl/fl mice were intravenously 
injected with adenovirus-Cre or adenovirus-GFP as a control. Age-matched Ildr2AAV KO and 
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Ildr2AAV GFP control mice were AAV-infected at the same time for parallel comparison. Ildr2Adv 
KO mice were euthanized 10 days post-injection.  No liver steatosis was seen despite complete 
Ildr2 ablation in liver (Fig. 2.3B,D,E). Ildr2Adv KO livers were heavier compared to Ildr2AAV KO 
mice (Fig. 2.3C), and also showed histological evidence of inflammation. However as these 
phenotypes were also present in the Ildr2Adv GFP control mice, we attributed them to the effects 
of adenovirus treatment (Fig. 2.3F) as has been documented previously [7-9]. 
 
Administration of adenoviral Ildr2 shRNA causes TG accumulation in Ildr2Alb KO mice 
We have produced three distinct models of hepatic Ildr2 KO:  a congenital, hepatocyte-
specific KO (Ildr2Alb KO); an acute, hepatocyte-specific, KO (Ildr2AAV KO); and an acute, liver-
specific KO (Ildr2Adv KO). None of these models showed the severe steatohepatitis observed in 
the adenoviral Ildr2 shRNA (ADKD) model.  Thus we were compelled to consider the possibility 
that some consequence of the shRNA antisense construct – unrelated primarily to the decrease in 
Ildr2 expression – had caused the steatosis.  
The original ADKD model was produced by treating mice with an adenovirally-delivered 
shRNA. Thus, either the adenovirus treatment or the shRNA itself may have triggered liver 
steatosis. We showed that adenoviral treatment alone does not cause hepatic steatosis, so we turned 
our attention to the shRNA. This shRNA was specifically designed to target exon 2 which is 
present in all isoforms of Ildr2 mRNA; however, the construct may have had “off target” effects 
on other genes as discussed below [15, 16, 33].  
To determine if other targets of the shRNA contributed to the KD liver phenotype, we 
infected Ildr2Alb KO mice with the original KD adenoviral shRNA. Since these mice do not express 
Ildr2 in the hepatocytes, any steatosis observed would be the result of shRNA targeting of other 
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genes affecting lipid metabolism. 10-week-old, male, Ildr2Alb KO or Ildr2flfl control mice were 
injected intravenously with the original adenovirus expressing Ildr2 shRNA (ADKD), or with 
control adenovirus expressing lacZ shRNA (AD-lacZ). Mice were euthanized at 10 days post-
adenovirus infection following a 24-hour fast. Gene expression analysis by qPCR confirmed that 
Ildr2 was completely ablated in Ildr2Alb KO mice, regardless of Adv treatment (Fig. 2.4A). In 
Ildr2flfl mice, Ildr2 shRNA (ADKD) reduced Ildr2 mRNA by about 50% vs. AD-lacZ treated 
Ildr2flfl mice (Fig. 2.4A). We did not observe gross liver steatosis, but chemical quantification of 
hepatic lipid content revealed that ADKD-treated mice had significantly increased hepatic TG 
compared to AD-lacZ treated mice, across both genotypes (3-fold in Ildr2flfl, 1.5-fold in Ildr2Alb 
KO) (Fig. 2.4B). Conversely, plasma TG was significantly decreased in Ildr2 shRNA treated 
Ildr2Alb KO and Ildr2flfl mice vs. AD-lacZ treated mice for both genotypes (Fig. 2.4C).  
These results confirm that the Ildr2 shRNA is sufficient to cause hepatic steatosis despite 
the preexisting absence of Ildr2.  Ildr2 expression was reduced by 50% in Ildr2 shRNA Ildr2flfl 
mice, indicating that acute partial loss of Ildr2 expression may contribute to the development of 
steatosis. However, the degree of steatosis and hypotriglyceridemia did not differ between Ildr2 
shRNA Ildr2flfl and Ildr2 shRNA Ildr2Alb KO mice, suggesting that Ildr2 expression is either 
irrelevant to the phenotype or has an equivalent effect at levels below a specific threshold, i.e. 
below 50%. In either case, the major trigger for hepatic steatosis is the Ildr2 shRNA, not Ildr2 
ablation per se. 
One explanation for these results is that the Ildr2 shRNA targets another gene or genes 
involved in hepatic lipid metabolism, and that KD of this gene or genes is primarily responsible 
for the gross steatosis in the original Ildr2 shRNA ADKD mice [6] and the less striking but still 
significantly increased TG accumulation observed here.  
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RNAseq analysis of Ildr2 shRNA ADKD vs. Ildr2Adv KO livers reveal candidate genes for 
shRNA off-target effects on hepatic steatosis 
Our Ildr2 shRNA was designed to target exon 2 of the Ildr2 mRNA, which is present in all 
known Ildr2 isoforms. The 19 base pair (bp) shRNA sequence, GTTCAAATCCTACTGCCAG, 
was tested for other gene targets by a BLAST search and no exact matches (other than Ildr2) were 
found. However it is possible that a partial match allowed for targeting and knockdown of a gene 
or genes essential for hepatic lipid homeostasis [16, 33].  
We performed RNA sequencing to determine which additional gene(s) might have been 
knocked down by the Ildr2 shRNA, and thus have contributed to development of steatosis in 
ADKD mice. Liver samples from ADKD and AD-lacZ mice (from our previously published 
ADKD study [6]) and Ildr2Adv KO mice were analyzed (Fig. 2.3). ADKD and AD-lacZ samples 
were harvested 3 days post Adv infection to increase the likelihood of detection of primary effects 
of knocking down the gene versus secondary gene changes resulting from with hepatic steatosis 
per se.  
RNAseq count expression data were analyzed with DEseq, a differential expression 
analysis program based on the negative binomial distribution [34]. Pairwise comparisons were 
made between Ildr2 shRNA (ADKD), AD-lacZ; Ildr2 shRNA ADKD and Ildr2Adv KO; and AD-
lacZ and Ildr2Adv KO, using the Benjamini-Hochberg test for multiple comparisons. Figure 2.5A-
C are “minus over average” (MA) scatter plots of differential gene expression profiles for each of 
the 3 comparisons. MA plots display the entire gene set, comparing fold change between samples 
(y-axis) to mean expression value (x-axis) with differentially expressed genes highlighted in red 
(Figure 2.5A-C). We screened for candidate genes that were: 1) significantly decreased in ADKD 
vs.  AD-lacZ, 2), significantly decreased in ADKD vs. Ildr2Adv KO, and, 3) unchanged between 
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AD-lacZ and Ildr2Adv KO livers indicating a specific effect of the KD Ildr2 shRNA shRNA (Fig. 
2.5D). Using these parameters, we obtained a list of 102 candidate genes (Table 2.2).  
This list was further refined by searching for genes that have been implicated in NAFLD 
genome-wide association studies (Ppp1ca) [35], genes associated with any other liver disease, 
(Dguok, Ass1) [36, 37], and obesity-related genes (Slc39a1) [38]. Since the shRNA was targeted 
to Ildr2’s exon 2 which encodes for an IgG domain, we identified genes that are part of the IgG-
like family (Neo1, Ptp4a1, Scn8a, Unc13b); additionally, we found a gene located near Ildr2 on 
chromosome 1 (Pogk) [5].  
Initial BLAST searches of the shRNA sequence yielded no complete match apart from 
Ildr2. However, searching for truncated portions of the 19-bp sequence yielded a partial match in 
Dgka. Dgka is one of the 102 candidate genes identified by RNAseq analysis (Table 2.2) and has 
63% homology to our Ildr2 shRNA sequence. The first 12 bp of the shRNA sequence, 
GTTCAAATCCTA, are a sequence match to exon 4 of the Dgka mRNA. Dgka expression is 
downregulated by 50-60% in ADKD livers compared to AD-lacZ and Ildr2Adv KO samples, 
suggesting that it could be targeted by the Ildr2 shRNA. Dgka encodes diacylglycerol kinase alpha 
(DGKα), which functions to convert diacylglycerides (DAGs) to phosphatidic acid [39]. DAG 
species are increased in cell lines derived from Dgka-null mice [40] similar to increases in DAG 
species observed in steatotic human liver samples [41]. These data suggest that loss of Dgka 
expression could result in the steatosis observed in our ADKD mice. In vitro and in vivo studies 
are currently underway to characterize the function of Dgka and other genes to determine their 





Discussion and Conclusions 
 In this study we describe several mouse models developed in an effort to replicate the 
hepatic steatosis phenotype of adenoviral Ildr2 shRNA KD mice. Using the Cre-loxP system, we 
created congenital and acute, hepatocyte-only and liver-specific Ildr2 KO mice. However none of 
these KO models recapitulated the phenotype of hepatic steatosis observed in the adenoviral Ildr2 
shRNA KD mice [6].  
RNAi-mediated knockdowns have been effectively used in many experimental settings, 
and are particularly useful in in vitro studies, and in instances in which a genetic knockout would 
be prohibitively expensive or difficult to make, or where the knockout is embryonically lethal. KD 
and KO models are generally quite similar, e.g., Pparα siRNA KD mice phenocopy the null 
transgenics [42] and connexin43 KO and KD mouse astrocytes have very similar transcriptional 
profiles [43]. 
However, discrepancies between RNAi-mediated KD and KO mouse models are not 
uncommon. siRNAs and shRNAs can have off-target effects due to sequence similarity to 
unintended gene targets [15, 16, 33]. As observed in this study, RNAi-mediated knockdowns can 
exhibit a more severe phenotype than the KO or null mutant due to disruption of the gene in a more 
mature developmental stage, when functional compensation is difficult [19, 44]. This situation has 
been documented, for example, for the genes thymosin β4 and Sprn/Prnp in mice, and ABP1 in 
Arabdopsis thaliana [45-47]. 
Our studies in which Ildr2 shRNA KD adenovirus was administered to Ildr2Alb KO mice 
revealed that lipid accumulation occurred with the adenovirus treatment, regardless of Ildr2 
genotype of the recipient mouse (Fig. 2.4). These experiments indicate that the hepatic lipid 
phenotype is due primarily to treatment with the adenovirus shRNA, rather than to loss of Ildr2 
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expression per se. They suggest that this shRNA targeted genes in addition to Ildr2. We identified 
Dgka, among other gene candidates, as a potential target of adenoviral Ildr2 shRNA in ADKD 
mice. Given its homology to the shRNA sequence, its reduced expression in ADKD mice, and its 
functional role in lipid metabolism [40, 41, 48], we propose that shRNA targeting of Dgka could 
account for the difference in lipid accumulation between ADKD and KO mice. 
Adenovirus is an efficient vector for introduction of gene products into cells both in vitro 
and in vivo. The most commonly used human adenovirus serotype 5 displays nearly exclusive liver 
tropism and thus is very useful for directing gene products to the liver. However, use of 
adenoviruses in these contexts can be problematic for several reasons. One obvious reason is that 
they are infectious agents and stimulate an inflammatory response in the infected cells [7-9]. This 
response can mask or confound the effect(s) of whatever biological molecules are being delivered 
to the cells. Another issue with adenovirus is that its tissue tropism, while fairly specific, is not 
exclusive, and it can affect tissues other than the target tissue [12]. Additionally, the various 
methods of measuring adenoviral titer make it difficult to control the amount of active virus that 
is administered in an experiment, which can lead to significant variation between experiments. The 
sensitivity of viral activity to temperature changes, i.e. freeze-thaw cycles, also contributes to 
experimental variability [49, 50]. 
 The experiments described here highlight some of the difficulties in working with 
adenoviruses. In addition to possible aberrant RNAi gene targeting, the striking phenotype of the 
original ADKD mice may also have been due to adenovirus-induced inflammation and /or 
targeting of extra-hepatic tissues. While we confirmed that Ildr2 expression was maintained in 
other tissues from ADKD mice [6], we cannot rule out that the Adv may have infected other 
organs. Another concern is that the amount of active Ildr2 shRNA adenovirus used to infect Ildr2Alb 
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KO mice may have decreased from its activity level at the time of ADKD infection. Although the 
same titer was used in both experiments (3x1011 optical particle units (OPU)/mouse), this titer only 
measures adenovirus concentration, not viral activity. A reduction in adenoviral activity could also 
explain the difference in lipid accumulation and severity of steatosis between ADKD mice and 
Ildr2Alb KO mice infected with Adv-Ildr2 shRNA. Use of the appropriate controls enabled us to 
deconvolute the effects of Ildr2 expression on hepatic steatosis in our various mouse models, 
however the confounds of using adenovirus as a primary delivery system remain a significant 
question. 
 We have conclusively shown that loss of Ildr2 whether specifically in hepatocytes or in all 
liver cells is not sufficient to cause hepatic steatosis. We propose that interruption of other gene(s) 
played a major role in the steatotic phenotype of the original ADKD. RNA-seq identified 102 
genes that are significantly reduced in ADKD mice vs. Ildr2Adv KOs or AD-lacZ controls (Table 
2.2). Of these candidates, one gene (Dgka) is a potential shRNA target with 67% sequence 
homology, thus the most likely candidate. Our future work will focus on studying the effects of 
Dgka KD, in addition to other candidates which could affect lipid metabolism in a manner similar 
to the ADKD. Hepatic lipid accumulation due to Adv-Ildr2 shRNA treatment has only been 
observed in mice with at least a 50% reduction in Ildr2 expression. Thus it is possible that KD of 
a candidate gene(s) interacts with Ildr2 hypomorphism to induce steatosis.   
Conclusions 
In these experiments, we sought to build upon our previous work [6] which implicated ILDR2 in 
mechanisms of lipid metabolism and hepatic steatosis by gene KD via adenoviral shRNA. 
Development of more precise genetic models, including several liver-specific Ildr2 KO mice, 
clarified that ILDR2 has a minimal function, if any, in hepatic lipid metabolism, and enabled us to 
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implicate other genes with potential roles in maintaining hepatic lipid homeostasis. This work has 
also highlighted some of the pitfalls in the use of both RNAi and viral delivery tools.  
These studies indicate that contrary to the inferences reached based on acute shRNA-
mediated KD, ILDR2 does not play a major role in hepatic lipid metabolism. Ildr2 was initially 
identified as modifier of diabetes susceptibility [5] and ongoing work in our lab has confirmed its 
role in beta cell function and glucose homeostasis (Chapter 3). Ildr2 is also highly expressed in 
the hypothalamus, leading us to postulate that it may also play a role in regulating body weight. 
Additionally, ILDR2, along with ILDR1 and ILDR3, are members of the angulin family which 
maintain membrane integrity at tricellular epithelial tight junctions [51, 52]. Our development of 
conditional KO mice to clarify the role of ILDR2 in the liver, can now facilitate the study of ILDR2 





We constructed a plasmid with loxP sites flanking exon 1 of the Ildr2 gene. This plasmid 
was injected into BL6/129 hybrid ES cells which were then implanted into pseudopregnant dams. 
Mice segregating for the Ildr2 floxed allele were backcrossed 9 times with C57BL6/J mice to 
produce mice with the floxed allele on a BL6 background. Mice possessing two floxed alleles 
(Ildr2fl/fl) were bred with albumin-Cre mice (B6.Cg-Tg(Alb-cre)21Mgn/J, Jackson Labs stock 
#003574) until all offspring segregated for 2 floxed alleles and one or no copies of Cre. 
All animal experiments were approved by Columbia Institutional and Animal Care Use 
Committee (Protocol# AAAH0707 and AAAR0416). Mice were housed in a 12-hr light/12hr-dark 
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vivarium, with ad libitum access to 5058 Purina PicoLab Mouse Diet 20 (9% fat) and water. High-
fat diet (HFD) fed mice received chow with 60% kcal from fat (Research Diets #D12492i). Where 
noted, blood was collected by submandibular bleeding. Fat and lean mass were measured with an 
EchoMRI Analyzer (Bruker Optics), calibrated using mouse carcasses [53]. 
Adenovirus production and administration 
Adenovirus expressing Ildr2 shRNA was designed, produced and amplified as previously 
described [6]. Adenovirus expressing lacZ shRNA was designed and produced as previously 
described [6], but amplification and purification procedures were performed by Welgen, Inc 
(Worcester, MA). Mice were administered 3x1011 OPU/mouse via tail vein injection. AAV-TBG-
Cre, AAV-TBG-eGFP, adenoviral-Cre, and adenoviral-GFP were obtained from the University of 
Pennsylvania Vector Core (Philadelphia, PA). Mice were administered 1.3x1011 genome 
copies/mouse via tail vein injection. 
Lipid measurements in tissue and plasma 
Capillary blood from submandibular bleeds was collected in heparinized tubes and 
centrifuged at 200 x g for 20 minutes at 4°C to separate plasma. Lipid extraction from liver was 
adapted from the Folch method [54]. Approximately 100 mg tissue were homogenized in 3 mL 
phosphate-buffered saline (PBS). 12 mL 2:1 chloroform: methanol (CHCl3: MeOH) were added 
and mixture was vortexed twice for 15 seconds each. After centrifuging at 3000 rpm for 10 
minutes, the organic lower layer was transferred to a 20-mL glass scintillation vial. An additional 
10 mL 2:1 CHCl3: MeOH were added to upper layer and vortexing and centrifugation were 
repeated. Organic lower layer was added to first extraction in scintillation vial. Solvent was dried 
down under nitrogen (N2) gas followed by lipid resuspension in 1 mL 15% Triton X-100 in CHCl3. 
Solvent was dried down again under N2 gas and remaining lipid was resuspended in 1mL H2O. 
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Triglyceride and total cholesterol in plasma and liver extracts were measured with the Infinity 
Triglycerides (Thermo Scientific) and Cholesterol E (Wako Diagnostics) kits, respectively. 
Glycogen measurement 
For glycogen extraction 100 mg tissue were homogenize in 1 mL H2O on ice, boiled for 
10 minutes, then centrifuged at 13,000 x g for 10 minutes to pellet insoluble material. Supernatant 
was transferred to a new tube and used for glycogen measurement. Glycogen was measured using 
a glycogen assay kit from Sigma-Aldrich (#MAK016) 
Primary hepatocyte and non-parenchymal cell isolation 
Primary hepatocytes were isolated as previously described [6]. The supernatant from 
primary hepatocyte centrifugation was collected and spun down at 500 x g, for 10 minutes at 4°C 
according to a protocol for isolating Kupffer cells by Xu, et al. [29]. The pelleted cells from this 
centrifugation were considered the non-parenchymal cell fraction. 
Hematoxylin and eosin histology 
Liver sections were fixed in aqueous zinc-buffered formalin (Anatech, Ltd.), sectioned and 
visualized by hematoxylin (Fisher) and eosin (Crystalgen) staining. Images were obtained using 
an Olympus IX73 inverted microscope (Olympus America). 
RNA extraction, reverse transcription and quantitative PCR 
Tissue and cell samples were homogenized in TRIzol® Reagent (Invitrogen) and extracted 
using the TRIzol® reagent protocol or the PureLink™ RNA Mini kit (Invitrogen). Reverse 
transcription was performed using the Transcriptor First Strand cDNA Synthesis kit (Roche). 
qPCR was performed using a Roche LightCycler® 480 instrument. qPCR primers are listed below. 
Tissue-specific standard curves for each gene (primer pair) were used to convert threshold crossing 
point (Cp) values to relative concentrations, which were then normalized to 36b4, Actb, and/or 
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Gapdh expression. In instances in which standard curves were not used, Cp values are shown, with 
lower Cp values indication greater mRNA expression. 
 
List of qPCR primers 
























RNA was extracted from liver samples as detailed above and sample integrity was assessed 
with an Agilent 2100 Bioanalyzer with all samples having RIN numbers greater than 8.0,  mRNA 
was isolated using a poly-A pulldown [55] and reverse transcription to generate cDNA. The cDNA 
was sequenced using single-ended sequencing on a HiSeq2000 according to manufacturer’s 
recommendations (Illumina; San Diego, CA). The pass filter (PF) reads were mapped 
to mouse reference genome mm9 using TopHat (version 2.0.4). TopHat infers novel exon-exon 
junctions ab initio, and combines them with junctions from known mRNA sequences (refgenes) 
as the reference annotation [56]. For each read, we allowed up to 3 mismatches and 10 multiple 
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hits during the mapping. Analysis was performed using DEseq software with Benjamini-Hochberg 










































Figures and Tables 




Figure 2.1: Albumin-cre, Ildr2 KO mice do not develop hepatic steatosis. 
(A) Schematic of the floxed Ildr2 allele. (B) Expression of Ildr2, isoforms 1 and 4 in livers of 23-
week old Ildr2Alb KO mice and littermate Ildr2fl/fl controls, fed chow or HFD for 17 weeks. 
Expression was measured by qPCR and normalized to 36b4, actb and Gapdh expression. (C) Body 
weight curves of HFD and chow-fed, Ildr2Alb KO mice. (D) Percent fat mass and lean mass of 
HFD and chow-fed, Ildr2Alb KO mice measured weekly by NMR. (E) Photographs of livers excised 
from HFD and chow-fed, Ildr2Alb KO mice at 23 weeks of age and hematoxylin and eosin staining 
of representative liver sections at 50X magnification. (F) Liver weight at 23 weeks of age. (G) 
Liver triglyceride and total cholesterol content (measured in duplicate). (H) Plasma triglyceride 
and total cholesterol concentration at 23 weeks of age after a 4hr. fast. n=4-5 mice per group. Data 
are represented as mean ± standard error (SEM) * p<0.05, ** p<0.01, *** p<0.001 for Ildr2Alb KO 
vs. Ildr2fl/fl control. + p<0.05, ++ p<0.01, +++ p<0.001 for chow vs. HFD (Two-tailed t-test or 










Figure 2.2: AAV Ildr2 KO mice do not develop hepatic steatosis. 
(A) qPCR expression of Ildr2, isoforms 1 and 4 in livers of 13-week old mice, 10 days after i.v. 
injection with AAV-TBG-Cre (Ildr2AAV KO) or AAV-TBG-GFP (Ildr2fl/fl controls). (B) Liver 
triglyceride and total cholesterol content at 10 days. (C) Plasma triglyceride and total cholesterol 
concentration at 10 days. (D) qPCR expression of Ildr2 (isoform 1 unless otherwise noted) in livers 
of 13-week old mice 2-12 days after i.v. injection with AAV-TBG-Cre (Ildr2AAV KO). AAV-TBG-
GFP was only administered for the 2-day timepoint (Ildr2fl/fl controls). (E) qPCR expression of 
Ildr2 in livers of 18-week old mice, 6 weeks after AAV injection (F) Liver triglyceride and total 
cholesterol measurements. (G) Plasma triglyceride and total cholesterol concentration at 20, 31 












Figure 2.3: Adenoviral Ildr2 KO mice do not develop hepatic steatosis. 
(A) qPCR expression of Ildr2, Tbg and F4/80 in hepatocyte or non-parenchymal cell fractions 
isolated from 12-week old wild-type (B6) mice. (B) qPCR expression of Ildr2 in livers of 11-week 
old mice, 10 days after i.v. injection with adenoviral-Cre (Ildr2Adv KO), adenoviral-GFP (Ildr2fl/fl 
controls), AAV-TBG-Cre (Ildr2AAV KO) or AAV-TBG-GFP (Ildr2fl/fl controls). (C) Liver weights 
at sac. (D) Liver triglyceride, total cholesterol and glycogen content. (E) Plasma triglyceride and 
total cholesterol concentration at sac following a 12hr fast (F) Hematoxylin and eosin staining of 
representative liver sections at 20X magnification. n=4-5 mice per group. * p<0.05, ** p<0.01, 






















Figure 2.4: Adenoviral Ildr2 shRNA in Ildr2 KO mice. 
(A) qPCR expression of Ildr2 in livers of 10-week old mice Ildr2Alb KO mice and littermate Ildr2fl/fl 
controls, 10 days after i.v. injection with ADKD or AD-lacZ. (B) Liver triglyceride and total 
cholesterol content. (C) Plasma triglyceride and total cholesterol concentration at sac following a 
24hr fast. n=5-6 mice per group. * p<0.05, ** p<0.01, *** p<0.001 for Ildr2fl/fl vs. Ildr2Alb KO; & 









Figure 2.5: RNAseq analysis 
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Figure 2.5: RNAseq analysis of AdV-KD vs. Ildr2Adv KO livers reveals candidate genes for 
shRNA off-target effects. 
“Minus over average” (MA) plots showing log2 fold change vs. normalized mean for each 
comparison. Red dots represent significantly upregulated or downregulated genes in (A) ADKD 
vs. AD-lacZ mice, (B) ADKD and Ildr2Adv KO mice, (C) AD-lacZ vs. Ildr2Adv KO mice. (D) 
Venn diagram illustrating how the 102 candidate genes were identified. The intersection of genes 
downregulated in ADKD mice vs. both AD-lacZ and Ildr2Adv KO was 204. 102 of these genes 
were not significantly changed in AD-lacZ vs. Ildr2Adv KO. These became the gene candidates 








Table 2.1: Mouse models - nomenclature and abbreviations 






















Ildr2Alb KO Hepatocytes E14.5 (upon 
albumin 
expression) 









































Rps19bp1 276 66 267 6.98E-28 6.49E-18 0.199 
Slc39a1 1314 422 1524 2.18E-26 1.42E-31 1.000 
Slc27a4 1167 473 1504 3.05E-23 1.04E-08 0.666 
Aldh4a1 5277 2521 6117 3.63E-19 9.96E-05 1.000 
Ndst1 3091 1464 3079 8.28E-19 1.37E-10 0.127 
Ppp1ca 3562 1720 4107 4.12E-18 1.20E-15 0.956 
Rab1b 3043 1523 3700 4.45E-16 3.10E-16 0.882 
2900097C17Rik 1326 662 1417 2.73E-14 5.36E-10 0.478 
Ptp4a1 529 246 558 4.76E-13 1.85E-06 0.463 
6330578E17Rik 2685 1434 2716 5.05E-13 2.98E-07 0.174 
Tbc1d13 852 426 1090 1.00E-12 5.29E-15 0.571 
Ubfd1 972 494 1155 1.28E-12 3.30E-12 1.000 
Gm98 1354 708 1630 1.54E-12 1.30E-12 0.948 
Tmem123 1090 563 1404 2.37E-12 5.18E-15 0.520 
Nt5dc2 336 151 374 1.68E-11 2.06E-09 0.819 
Neo1 671 345 676 7.21E-11 1.09E-05 0.224 
Sumf2 291 135 290 9.58E-10 8.90E-06 0.283 
Acpl2 266 124 338 4.16E-09 9.22E-11 0.711 
Pcgf2 181 79 210 2.44E-08 2.32E-04 1.000 
Cpsf2 783 448 841 4.44E-08 9.82E-06 0.539 
Wfdc2 201 59 190 5.30E-08 6.97E-09 0.260 
Ccdc50 1569 946 2019 7.78E-08 1.72E-10 0.518 
Tspan4 626 359 772 1.70E-07 1.80E-04 0.876 
Reck 81 27 87 4.09E-07 6.94E-06 0.776 
Pef1 1057 642 1345 4.99E-07 3.00E-09 0.599 
Scpep1 1018 618 1254 5.33E-07 2.74E-08 0.814 
Diablo 560 326 548 7.33E-07 2.44E-03 0.148 
Icmt 1088 675 1172 1.65E-06 1.36E-04 0.535 
Celf1 3216 2074 3415 1.96E-06 4.12E-04 0.405 
Dgka 160 75 187 2.38E-06 1.57E-06 1.000 




Stat6 1590 1019 1825 4.42E-06 1.33E-05 0.946 
Chtf8 1247 792 1459 4.68E-06 5.19E-06 1.000 
Dpp8 1734 1118 1816 5.03E-06 1.21E-03 0.352 
Ipo5 1941 1256 2423 5.06E-06 2.05E-04 0.748 
Snx4 802 500 980 6.65E-06 6.53E-07 0.884 
1810011O10Rik 785 491 927 7.77E-06 4.37E-06 1.000 
Trappc9 395 232 451 8.09E-06 2.62E-05 0.930 
Erp29 949 602 1228 8.70E-06 2.19E-08 0.489 
Eif3h 2005 1332 2224 2.32E-05 3.12E-04 0.712 
Pja2 1062 693 1459 3.17E-05 1.63E-09 0.191 
Arl4d 531 312 756 4.58E-05 8.90E-05 0.370 
Cdt1 233 121 366 5.32E-05 6.90E-05 0.207 
Rab34 205 97 260 6.48E-05 3.52E-09 0.749 
Pogk 155 82 225 7.69E-05 6.56E-09 0.216 
Gtf3c1 1771 1062 1764 9.27E-05 1.34E-03 0.140 
Pofut1 410 255 540 1.02E-04 2.24E-07 0.454 
Atr 601 389 716 1.29E-04 8.64E-05 1.000 
Tbc1d20 807 534 894 1.38E-04 1.04E-03 0.733 
Rpa2 295 155 341 1.44E-04 6.00E-04 1.000 
Nol3 24 4 36 1.49E-04 1.04E-07 0.533 
Psmd14 1404 955 1472 1.54E-04 9.94E-03 0.359 
Tax1bp3 72 30 82 1.58E-04 2.18E-04 0.969 
Tab2 1916 1221 2563 1.77E-04 2.59E-10 0.272 
Cenpm 148 62 167 1.77E-04 6.02E-07 0.915 
Adss 1756 1163 2309 1.97E-04 5.07E-04 0.602 
Zdhhc2 178 74 216 1.97E-04 2.57E-04 1.000 
Ern1 836 554 886 2.51E-04 5.07E-03 0.454 
Sox12 129 68 142 2.55E-04 3.50E-03 0.850 
Slc4a4 3541 2086 3876 2.74E-04 5.33E-07 0.621 
Setd8 1595 1039 1698 2.80E-04 1.04E-03 0.440 
S100a16 385 245 425 2.90E-04 1.66E-03 0.753 
Rassf5 334 210 429 3.19E-04 4.41E-06 0.623 
Tmem189 331 208 364 3.42E-04 1.95E-03 0.751 
Plod3 447 290 618 3.49E-04 6.00E-08 0.220 
Scn8a 38 12 46 4.04E-04 1.18E-04 1.000 
Pcnxl3 1147 795 1261 5.32E-04 4.14E-03 0.677 




2310022B05Rik 445 291 599 5.60E-04 5.46E-07 0.336 
Vps39 584 391 754 5.91E-04 4.03E-06 0.543 
Nacc1 1123 783 1361 7.35E-04 9.58E-05 0.911 
Zswim7 182 107 196 7.37E-04 5.19E-03 0.680 
Entpd5 11076 7174 13493 7.81E-04 9.33E-08 0.877 
Ass1 4516 2710 8270 8.68E-04 2.85E-03 0.133 
Pip4k2c 656 449 870 9.94E-04 1.80E-06 0.382 
Dguok 231 144 250 1.15E-03 6.84E-03 0.693 
Hfe 1107 783 1321 1.41E-03 4.08E-04 1.000 
Atg16l2 212 133 238 2.03E-03 3.74E-03 0.892 
P4hb 21192 15697 28758 2.26E-03 1.49E-05 0.181 
Ctsz 4039 2972 4668 2.40E-03 2.43E-03 0.977 
P4ha2 131 59 153 2.61E-03 2.92E-03 1.000 
Slc34a2 47 13 38 2.86E-03 6.03E-03 0.350 
Nle1 85 45 123 3.35E-03 5.77E-06 0.358 
Grina 3684 2736 4162 3.76E-03 8.64E-03 0.835 
Gnl3l 445 311 630 5.38E-03 8.05E-07 0.155 
Unc13b 258 132 309 5.41E-03 3.97E-06 0.998 
Tesk1 476 333 563 5.89E-03 1.98E-03 1.000 
Mcm3 371 248 546 6.06E-03 4.12E-03 0.346 
Maged1 2143 1603 2458 6.93E-03 8.08E-03 0.938 
Frmd8 522 359 738 6.97E-03 1.74E-07 0.139 
Eaf1 1713 1276 2136 7.07E-03 7.08E-04 0.725 
Inppl1 1205 890 1596 7.12E-03 1.70E-05 0.351 
4732418C07Rik 478 338 563 7.12E-03 3.10E-03 1.000 
Slk 1319 980 1676 8.11E-03 1.49E-04 0.606 
Comtd1 99 57 151 8.13E-03 1.72E-06 0.163 
Dock8 823 553 1011 8.68E-03 1.93E-05 0.848 
Pdia4 4016 2883 4695 8.70E-03 5.53E-04 1.000 
Echdc3 948 700 1165 9.08E-03 7.53E-04 0.828 
Galns 352 246 490 9.20E-03 6.04E-06 0.228 
1110008P14Rik 390 275 474 9.37E-03 1.52E-03 0.928 
Edem1 3313 2515 4237 9.87E-03 1.16E-04 0.533 
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Chapter 3: The role of ILDR2 in pancreas islet function 
 
Introduction 
 Diabetes mellitus is highly prevalent affecting one in eleven adults worldwide (International 
Diabetes Federation Diabetes Atlas - 7th Edition, http://www.diabetesatlas.org/). Diabetes 
mellitus type 2 (T2D) accounts for ~95% of all instances of diabetes in adults, hence a major 
focus of metabolic research over several decades has been to understand the environmental and 
genetic contributors to this disease. Multiple genetic loci have been associated with T2D in 
humans [1-3] but the genetic components contributing to disease risk remain poorly understood. 
 Our laboratory utilized mouse strain differences along with the close association of T2D with 
obesity to uncover novel genes modulating T2D susceptibility [4]. Intercrossing T2D-susceptible 
(DBA) and T2D-resistant (BL6J) Lepob/ob mice, we mapped several disease-relevant loci, then 
introgressed implicated DBA genetic intervals into C57BL/6J animals segregating for Lepobto 
further interrogate each genetic locus. We identified a 1.8Mb interval on chromosome 1 for which 
the DBA allele was associated with diabetes-related phenotypes, and established the causative 
gene as immunoglobulin-like domain-containing receptor 2 (Ildr2, previously Lisch-like), or 
C1orf32 in humans. Initially, we demonstrated that Ildr2 hypomorphic mice (derived from 
B6.DBA congenic lines) segregating for Lepob were hyperglycemic and hypoinsulinemic, with 
decreased glucose tolerance, reduced beta cell replication, and decreased beta cell area. Zebrafish 
treated with Ildr2 morpholinos have defects in pancreas and liver development [4]. As discussed 
in Chapter 2, additional efforts in our lab to understand the role of ILDR2 have focused on its 




 In the studies described in this chapter, we utilized the Cre-loxP system to design beta cell-
specific (RIP2-cre) and pancreas-specific (Pdx-cre) Ildr2 knockout (KO) mice. The RIP2-cre and 
Pdx-cre constructs have been widely used to elucidate the roles of several genes in pancreas 
development, function, and the pathophysiology of diabetes and various pancreatic cancers [5-12]. 
RIP2-cre mice in particular have been extensively characterized in various experimental contexts, 
resulting in a number of caveats regarding their use. RIP2-cre is expressed mainly in beta cells, 
but also in a subset of hypothalamic neurons [13]. Thus, some RIP2-cre mediated KOs have 
exhibited feeding and body weight phenotypes due to hypothalamic effects of the gene KO [14-
16]. RIP2-cre mice have also been shown to develop glucose intolerance, reduced insulin 
secretion, and age-dependent changes in beta cell mass in the absence of any floxed gene [6, 7, 
17].  These confounding effects necessitate the careful phenotyping of KO models utilizing the 
RIP2-cre construct, and, preferably, the use of “Cre-only” controls which do not segregate for any 
floxed alleles. 
 Here we continue our investigation into the role of ILDR2 in T2D by characterizing RIP2-cre 
and Pdx-cre Ildr2 KO mouse models. Assessing hyperglycemia, insulin secretion, and islet gene 
expression, we compare the phenotypes of these two KO models and discuss how they elucidate 
the role of ILDR2 in the beta cell and pancreas. 
 
Results 
Generation of pancreas-specific and beta cell-specific Ildr2 KO mice 
 The development of Ildr2 floxed mice (Ildr2fl/fl) is described in Chapter 2. Ildr2 floxed mice 
were crossed with mice expressing Cre recombinase under the control of the rat insulin II promoter 




et al. [8]). Mice were intercrossed until all offspring expressed two copies of the floxed Ildr2 allele 
and one or zero copies of respective Cre gene. Mice expressing RIP2-cre were β cell-specific 
knockouts (KO) and those expressing Pdx-cre were pancreas-specific KOs. These KOs will be 
referred to as RIP2-KO and Pdx-KO for the remainder of the text. Littermates without Cre 
(Ildr2fl/fl) were used as controls.  
 As detailed above, KO mice developed using the RIP2-cre mouse have to be carefully 
phenotyped with the understanding that changes in glucose homeostasis and islet biology may be 
influenced by the Cre construct rather than a direct consequence of gene ablation. In our studies 
with RIP2-cre Ildr2 KO mice, we compare them with Pdx-cre Ildr2 KO mice to assess the specific 
effect of Ildr2 ablation. The different phenotypes of RIP2-KO and Pdx-KO mice are summarized 
in Table 3.1. 
 
Pdx-KO and RIP2-KO mice are glucose-intolerant 
We assessed these KO mice for phenotypes seen in the B6.DBA Chr 1q23 congenic mice 
[4]. Male, chow-fed RIP-KO and Pdx-KO mice displayed normal body weights (8-22 weeks of 
age) (Fig. 3.1A,C) and fasting blood glucose levels compared to Ildr2fl/fl littermate controls (Fig. 
3.1E,F). Fat mass in RIP2-KO mice was slightly increased vs. controls from 17 weeks to 22 weeks 
old, but Pdx-KO mice showed no difference in fat mass at 20 weeks (Fig. 3.1B,D). 
Intraperitoneal glucose tolerance testing (ipGTT) was performed at 8 weeks old. RIP2-KO 
and Pdx-KO mice displayed decreased glucose tolerance compared to littermate Ildr2fl/fl controls 
as indicated by increased area under the curve (AUC) for glucose (Fig. 3.1G,H). An additional 
ipGTT with increased glucose bolus (2mg/g vs. 1mg/g previously) was administered to RIP2-KO 




increased glucose AUC (Fig. 3.1I). Plasma insulin was decreased in RIP2-KO mice vs. Ildr2fl/fl 
controls, resulting in decreased insulin: glucose ratios (Fig. 3.1J,K).  These results indicate that 
RIP2-KO and Pdx-KO mice are glucose intolerant, which may be due to reduced insulin secretion. 
 
HFD feeding does not trigger diabetic phenotypes in Pdx-KO and RIP2-KO mice 
Because the Ildr2 gene was first identified in obese (leptin-deficient) mice and confirmed 
in high-fat diet fed wild-type C57BL/6J mice, we hypothesized that additional metabolic stress 
may be necessary to produce an easily observable phenotype. To test this possibility, RIP2-KO 
and Pdx-KO mice and Ildr2fl/fl littermate controls were fed a high-fat diet (HFD; 60% kcal from 
fat) from 6-30 weeks of age. While HFD-fed Pdx-KO mice gained weight similarly to Ildr2fl/fl 
HFD-fed mice and showed no difference in fasting (4hr) blood glucose concentration (Fig. 
3.2B,D), RIP2-KO mice gained less weight when fed the HFD and had slightly, but consistently, 
lower fasting blood glucose concentrations than Ildr2fl/fl controls (Fig. 3.2A,C). RIP2-KO mice 
also exhibited reduced plasma insulin concentrations after 13 weeks of HFD feeding (Fig. 3.2E).  
However, HFD-fed RIP2-KO mice had significantly lower body weight than controls, a difference 
which, itself, could reduce circulating insulin concentration. 
We measured glucose tolerance in HFD mice at 16 weeks old. As with the non-obese chow 
animals, both RIP2-KO and Pdx-KO mice exhibited impaired glucose tolerance, with significantly 
increased blood glucose concentrations at 15 and 60 minutes post glucose bolus (Fig. 3.2G,H). 
However, glucose AUC was not significantly increased. An ipGTT performed 8 weeks later, at 24 





RIP2-KO mice show decreased insulin secretion by oral glucose tolerance test (OGTT), but 
increased glucose-stimulated insulin secretion (GSIS) in isolated islets 
 To investigate whether glucose intolerance in RIP2-KO mice was due to decreased insulin 
secretion, we performed an oral glucose tolerance test (OGTT). Delivering glucose directly to the 
gut, we exploited the incretin effect to stimulate an increased insulin response. 10-week old, low-
fat chow fed, male mice were gavaged with 2 mg/g body weight glucose and blood was collected 
at 0, 15 and 60 minutes post bolus. Confirming our results from ipGTTs, RIP2-KO displayed 
glucose intolerance with increased glucose AUC (Fig. 3.3A). They also exhibited decreased 
plasma insulin concentrations compared to Ildr2fl/fl controls at 15 minutes post glucose bolus (Fig. 
3.3B).  
We also performed static glucose-stimulated insulin secretion (GSIS) assays on islets 
isolated from 8-week old, chow-fed RIP2-KO and Ildr2fl/fl mice. Islets were incubated in basal 
medium containing 2.8mM glucose, followed by stimulation with 16.8mM glucose. Adjusted for 
insulin content, RIP2-KO islets showed increased insulin secretion compared to Ildr2fl/fl controls 
(Fig. 3.3C).  
 
Islets from Pdx-KO mice show impaired calcium signaling and decreased glucose- and 
potassium-stimulated insulin secretion  
 Islets isolated from 8-10 week old Pdx-KO mice and Ildr2fl/fl littermate controls were 
subjected to microfluidic perifusion at the University of Illinois JDRF Microfluidic-Based 
Functional Analysis Facility. Islets were stimulated with 14mM glucose and 30mM KCl and 




 Calcium signaling was impaired in Pdx-KO islets vs. Ildr2fl/fl islets (Fig. 3.4A), but 
mitochondrial potential was normal (Fig. 3.4B). Pdx-KO islets also showed decreased insulin 
secretion and reduced insulin AUC by both glucose and potassium stimulation compared to Ildr2fl/fl 
islets (Fig. 3.4C,D). These results suggest a mechanism for the impaired glucose tolerance 
observed in Pdx-KO mice and indicate that Ildr2 may play a role in maintaining calcium signaling 
in islets, possibly by regulating intracellular calcium concentrations at the ER membrane [18-20].  
Decreased insulin secretion was observed in RIP2-KO mice in vivo but not in vitro, which 
could indicate defects in islet vascularization [21]. However, since dysregulation of insulin 
secretion is one of the confounding effects of RIP2-cre expression [6], we are inclined to accept 
the results in Pdx-KO mice as more reliable. 
 
Islets of RIP2-KO mice, but not Pdx-KO mice, exhibit beta cell hyperplasia 
To understand how changes in islet development and structure might affect the observed 
phenotypes of glucose intolerance and insulin secretion, pancreata from 23-29 week old, chow-
fed, male RIP2-KO and Pdx-KO and Ildr2fl/fl control mice were fixed, sectioned and 
immunostained for insulin and glucagon (Fig. 3.5A,G). RIP2-KO mice had a 2-fold increase in 
beta cell area compared to controls (Fig. 3.5B), due to increases in both number of islets (Fig. 
3.5C) and beta cell number (Fig. 3.5D,E), although alpha cells were not increased in RIP2-KO 
mice (Fig. 3.5F). In contrast, there was no change in islet size or beta/alpha cell ratio in Pdx-KO 






Ildr2 expression is completely ablated in Pdx-KO islets, but retained in the islets of RIP2- 
KO mice 
 To confirm that Ildr2 is knocked out in the RIP2-KO and Pdx-KO mice, we isolated islets 
from 10-24 week male RIP2-KO and Pdx-KO mice and controls, and measured Ildr2 gene 
expression by qRT-PCR. Surprisingly, Ildr2 expression in islets of RIP2-KO mice was comparable 
to Ildr2fl/fl controls (Fig. 3.6A). In Pdx-KO mice however, islet Ildr2 expression was completely 
ablated (Fig. 3.6D). Cre was expressed in both RIP2-KO and Pdx-KO islets (Fig. 3.6C,F). Primers 
targeted to amplify only the floxed exon 1 segment also gave the same result: Ildr2 was knocked 
out in Pdx-KO islets but not RIP2-KO islets (Fig. 3.6B,E). These results suggested that Ildr2 
expression in non-beta islet cell populations might be masking KO in the beta cells of RIP2-KO 
mice.  
Because of previous reports of both RIP2-cre [13] and Pdx-cre constructs [22] expression 
in the hypothalamus, we also measured Ildr2 and Cre expression in the hypothalami of our RIP2-
KO and Pdx-KO mice and littermate Ildr2fl/fl controls. Ildr2 expression was unchanged in the 
hypothalamus of both RIP2-KO and Pdx-KO mice (Fig. 3.6G,I), although Cre expression was 
detected in both (Fig. 3.6H,J). 
To investigate Ildr2 expression in non-beta islet cell populations, we interrogated mouse 
[23] and human (Bryan González, personal communication) islet single cell sequencing data for 
Ildr2 expression. Mouse alpha and beta cell transcriptome sequencing analysis indicate that Ildr2 
is expressed at relatively low levels in both beta and alpha cells [23]. For comparison, Arx, an 
alpha cell-specific transcription factor, had higher expression in beta cells than Ildr2. Conversely, 
in alpha cells, expression of the beta cell-specific gene Mafa was an order of magnitude higher 




delta, gamma, or epsilon cells, human islet single cell sequencing data showed that Ildr2 was 
expressed at equivalently low levels in all five endocrine cell populations.  
These data suggest that Ildr2 may be expressed in some non-endocrine cell population in 
pancreatic islets. We hypothesize that islet macrophages could be the source of Ildr2 expression. 
Islet macrophages play an important role in beta cell replication and proliferation, both in islet 
development [24] and after pancreatic injury [25]. In disease states, such as Type 1 or Type 2 
diabetes, islet macrophages become activated to release inflammatory cytokines contributing to 
disease progression [26, 27]. Ildr2 is expressed in tissue macrophages in liver (Fig. 2.3) and 
adipose tissue [28]. We propose that Ildr2 may be expressed in islet macrophages at higher levels 
than in beta cells, and that this expression may be what was observed in RIP2-KO islets. 
 
The RIP2-cre construct includes an hGH minigene which may affect beta cell function in 
RIP2-KO mice.  
 Several pancreas cell-specific Cre constructs (RIP-, MIP-, and Pdx-Cre’s), include a 2.1kb 
human growth hormone (hGH) “minigene” to improve Cre expression [29]. At the time these Cre 
constructs were designed, it was believed that the hGH gene was not expressed and would not 
produce any active growth hormone. However, recent publications have shown that hGH is 
expressed in Cre-expressing mice and may cause diabetic phenotypes independent of any 
consequence for co-segregating floxed genes. The Cre construct used to create our RIP2-cre, Ildr2 
KO mice was developed and reported by Magnuson and others [5, 17]. This Cre construct includes 
the hGH minigene; and Cre mice – not segregating for any floxed allele – have been reported to 




mass [6, 13, 17]. The construct used to create the Pdx-cre Ildr2 KO mice does not contain an hGH 
minigene [8, 29].  
 To determine whether hGH expression in our KO mice could account for the observed 
phenotypes, we measured hGH expression in islets of RIP2-KO and Pdx-KO mice, and Ildr2fl/fl 
controls. hGH was highly expressed in islets from RIP2-KO mice, but not in Pdx-KO islets (Fig. 
3.7A). Brouwers et al. suggest that hGH acts as a lactogen in mouse beta cells [29, 30], stimulating 
prolactin receptor signaling which is responsible for increases in beta cell mass and insulin 
secretion that accompany pregnancy [31, 32]. Serotonin biosynthesis genes are also  upregulated 
by lactogen signaling in pregnancy [33] consistent with the role of serotonin to increase beta cell 
proliferation [34]. Tph1, encoding tryptophan hydroxylase 1 which catalyzes the rate–limiting step 
of serotonin biosynthesis, was found by others to be upregulated in mice expressing Cre-hGH 
constructs [29]. We measured expression of Tph1 in islets of RIP2-KO and Pdx-KO mice, and 
Ildr2fl/fl controls. Tph1 expression was highly induced (~200-fold) in RIP2-KO mice but not in 
Pdx-KO or control mice (Fig. 3.8B). These results – in the context of the results in the Pdx-KO 
mice – suggest that the glucose intolerance and beta cell hyperplasia observed in RIP2-KO mice 
may be a consequence of Cre-mediated hGH expression, rather than of Ildr2 KO in beta cells.  
 
Discussion and Conclusions 
We used beta cell-specific RIP2-cre Ildr2 KO mice and pancreas-specific Pdx-cre Ildr2 
KO mice to confirm a role for ILDR2 in beta cell biology, a role previously suggested by positional 
cloning of a quantitative trait locus in leptin-deficient mice [4]. Pdx-KO mice display impaired 
glucose tolerance in vivo, and decreased calcium signaling in conjunction with reduced insulin 




mice also show impaired glucose tolerance with variable insulin secretion, and beta cell 
hyperplasia. However, the results in RIP2-KO mice are confounded by the expression of hGH and 
its downstream effects on beta cell development and  function [29] the  phenotypes of these animals 
are consistent with previously described consequences of the RIP2-cre construct and hGH 
expression on insulin/glucose homeostasis in transgenic mice. RIP2-cre mice not segregating for 
any floxed allele have been reported to display glucose intolerance [6, 13], decreased insulin 
secretion [6] and age-dependent changes in beta cell mass [7].  
Comparison of RIP2-KO mice with Pdx-KO phenotypes indicates that some aspects of 
RIP2-KO phenotypes are probably due to Ildr2 ablation, but in the absence of ‘Cre-only’ controls 
we cannot isolate specific effects of Ildr2 KO vs. hGH expression. All of our control mice 
segregated for Ildr2 floxed alleles with no Cre construct (Ildr2fl/fl mice). To elucidate which 
phenotypes in RIP2-cre Ildr2 KO mice are specifically due to Ildr2 KO, we would need to compare 
KO mice with controls expressing the Cre construct in the absence of the floxed alleles, as the 
presence of the hGH minigene may have masked more subtle effects of the beta cell-specific 
knockout of Ildr2.  We are in the process of generating these mice for such studies.  
Pdx-KO mice do not possess the hGH minigene (Fig. 3.7), and thus are free of these 
confounding issues. We conclude that phenotypes observed in Pdx-KO mice – glucose intolerance, 
decreased calcium signaling and decreased glucose- and potassium-stimulated insulin secretion – 
are the primary effects of Ildr2 knockout in pancreatic islets. 
The association of decreased insulin secretion with decreased calcium signaling in Pdx-
KO islets suggests that ILDR2 may modulate calcium signaling in beta cells to regulate insulin 
secretion. These results may reflect a specific role for ILDR2 in regulating cellular calcium 




proteins which function to regulate its calcium concentration, e.g. sarco/endoplasmic reticulum 
Ca2+ ATPase (SERCA) [35], and PKR-like ER kinase (PERK) [36] which also modulates ER 
stress. Since ILDR2 is located in the ER membrane, our data suggest that it may play a similar role 
in maintaining ER calcium concentration. As discussed in Chapter 1, in a protein screen (2D-
PAGE) in W87* Ildr2 “deficient” mice, several calcium regulatory proteins were decreased, 
suggesting a functional role for ILDR2. 
Since Pdx-KO mice lack Ildr2 in all islet, exocrine, and ductal cells in the pancreas, the 
phenotype observed in these mice may not be due solely to beta cell defects. Calcium signaling 
also regulates glucose-stimulated hormone secretion in alpha and delta cells [37], thus defects 
related to Ildr2 ablation in these cell types may contribute to the overall phenotype of Pdx-KO 
mice.  
Islet macrophages may also be affected. Ildr2 expression in RIP2-KO islets highlighted the 
relatively low Ildr2 expression in endocrine cells, and possible expression in another cell-type, i.e. 
macrophages. Ildr2 is expressed in liver and adipose tissue macrophages suggesting that Ildr2 may 
have a role in islet macrophages as well. Loss of Ildr2 in macrophages could possibly stimulate 
pro-inflammatory signaling leading to decreased beta cell function [27]. Thus, one explanation for 
Ildr2 expression in RIP2-KO islets could be that islet macrophages in RIP2-KO mice expressed 
Ildr2, while Pdx-KO islet macrophages were knocked out due to broader cell type expression by 
Pdx1. A caveat to this hypothesis, however, is that the Pdx1 gene may not be expressed in islet 
macrophages to cause Ildr2 ablation. An essential transcription factor for the development of 
pancreatic precursor cells, Pdx1 has not been identified to play a role in the myeloid cell lineages 
from which macrophages develop. However, Pdx1 is expressed in differentiated THP-1 cells, a 




recognize ILDR2 in pancreatic tissue, hindering our ability to specify cell-specific expression by 
immunohistochemistry. Thus to determine if Ildr2 is knocked out in islet macrophages, it will be 
necessary to isolate different islet cell populations and profile them separately for Ildr2 gene 
expression. 
Pdx-KO mice have afforded initial insights regarding the role of Ildr2 in pancreatic islet 
cells. Because the pancreas is a complex organ with diverse functions, additional cell-specific KO 
mouse models will be required to decipher specific effects of Ildr2 KO. This work provides the 
first description of specific role for Ildr2 in beta cell function since its designation as a modifier of 
diabetes susceptibility [4]. Despite concerns with the RIP2-cre mouse models, these initial 
observations suggest that further investigation into the function of ILDR2 in the pancreatic islet 




Mice bearing 2 floxed alleles of Ildr2 (Ildr2fl/fl) were developed as described in Chapter 2. 
Ildr2fl/fl were bred with rat insulin promoter II cre (B6.Cg- Tg(Ins2-cre)25Mgn, Jackson Labs stock 
#003573) or Pdx1 promoter-cre mice (B6.FVB- Tg(Pdx1-cre)6Tuv, Jackson Labs stock #014647) 
until all offspring segregated for 2 floxed alleles and one or no copies of Cre. 
All animal experiments were approved by Columbia Institutional and Animal Care Use 
Committee (Protocol# AAAH0707 and AAAR0416). Mice were housed in a 12-hr light/12hr-dark 
vivarium, with ad libitum access to 5058 Purina PicoLab Mouse Diet 20 (9% fat) and water. High-




and lean mass were measured with an EchoMRI Analyzer (Bruker Optics), calibrated using mouse 
carcasses [39]. 
Glucose tolerance tests 
For intraperitoneal (ip) GTT, mice were i.p. injected with 1-2 mg glucose (50% dextrose, 
Hospira, Inc) per gram body weight following an overnight fast (16-18 hours). Blood glucose was 
measured at indicated time intervals after glucose bolus using a FreeStyle Lite (Abbott) or 
AlphaTRAK 2 (Zoetis) glucometer. For plasma glucose and insulin measurements, blood was 
collected by submandibular bleed.  
For oral GTT, mice were gavaged with 2 mg glucose per gram body weight following an 
overnight fast (16-18 hours). Blood glucose was measured at indicated time intervals after glucose 
bolus using a glucometer. For plasma insulin measurements, blood was collected from the tail 
vein. Plasma glucose was measured enzymatically (Autokit Glucose, Wako Diagnostics) and 
plasma insulin was measured using mouse insulin ELISA kit (CrystalChem or Mercodia). 
 Mouse islet isolation and glucose-stimulated insulin secretion (GSIS) assay 
Mouse islets were isolated as previously described [40] and incubated overnight in RMPI 
media (Thermo Fisher, 11879) with 10% FBS, 1% Pen Strep, 1% GlutaMAX, 5.6mM glucose at 
37°C, 5% CO2. For RNA extraction, islets were washed 2x in phosphate-buffered saline (PBS) 
and pelleted at 1000 rpm for 2 min. For GSIS, islets were washed and incubated in Krebs-Ringer-
bicarbonate-HEPES buffer (KRBH, 140 mM NaCl, 3.6 mM KCl, 0.5 mMNaH2PO4, 0.5 
mM MgSO4, 1.5 mM CaCl2, 2 mMNaHCO3, 10 mM HEPES, 0.1% BSA) [41] with 2.8mM 
glucose for 1 hour 37°C, 5% CO2. Media was discarded and islets were incubated in 2.8 mM 
glucose for 1 hour. This medium was collected (low glucose) and islets were incubated in 16.8 




high salt buffer for insulin content measurement. Insulin concentration was measured using mouse 
insulin ELISA kit (Mercodia). 
Islet perifusion analysis 
After overnight culture post islet isolation, the islets were transferred into a petridish with 
5 µM fura-2AM (Molecular Probes, Inc.) and 2.5 µM Rhodamine 123 (Sigma) for 30 min at 37 °C 
in Krebs-Ringer buffer (KRB) containing 2 mM glucose (KRB2). Islets were then introduced into 
temperature-controlled microfluidic device [42] through the inlet microchannel and mounted on 
inverted epifluorescence microscope (Leica DMI 4000B). The loaded islets were perifused by a 
continuous flow of KRB2 at 37°C (pH 7.4) for 10 minutes. Multiple islets were simultaneously 
observed for calcium influx, mitochondrial potentials, and insulin secretion kinetics with a 10X 
objective. The islets were stimulated with 14mM glucose for 25 min, washed with 2 mM glucose 
for 15 minutes, and stimulated again with 30mM KCl for 15 min, and followed by washing by 2 
mM glucose for 10 minutes. Dual-wavelength fura-2AM is excited at 340 and 380 nm, and changes 
in [Ca2+]i are expressed as F340/F380 (%). Rhodamine 123 is excited at 495 nm and expressed as 
percentage changes. Emission of fura-2AM and Rhodamine 123 are 510 and 530 nm, respectively. 
Excitation wavelengths were controlled by means of corresponding excitation filters (Chroma 
Technology) mounted in a Lambda DG-4 wavelength switcher. Emissions of fura-2AM and 
Rhodamine 123 fluorescence were filtered using a Fura2/FITC polychroic beamsplitter and double 
band emission filter (Chroma Technology. Part number: 73.100bs). A shutter controller was used 
to avoid continuous exposure of fluorescently stained cells to the excitation light. Time-lapse 
images were recorded with short exposure times between 0.1-0.3 s per image. A high-speed, high-
resolution charge-coupled device (CCD, Retiga-SRV, Fast 1394, QImaging) was used for imaging 




Perifusates were collected by fraction collector (Gibson, FC203B Fraction collector) at 1mL/min. 
Dynamic insulin secretions were measured by mouse insulin ELISA kit (Alpco). 
Pancreas histology and islet cell counting 
Mouse pancreata were fixed in 10% formalin and paraffin-embedded. For morphometric 
analysis of β cell area and islet number, 3 animals of each genotype were analyzed. For each 
pancreas, 6 sections ∼100 μm apart, were immunostained with insulin (Dako #A0564) and DAB 
peroxidase (Dako) were covered systematically by accumulating images from non-overlapping 
fields using a Nikon Eclipse E400 bright-field microscope (Nikon Instrument, Inc.). Images were 
captured using a Spot digital camera (Diagnostic Instruments), and analyzed using Image-Pro Plus 
software. (Media Cybernetics). Results are expressed as percentage of the total surveyed 
pancreatic area occupied by β cells (Fig. 3.5B). For immunofluorescent analysis of islet cell 
number, 3-4 animals of each genotype were analyzed. For each pancreas, 3 sections, 200-300 μm 
apart were immunostained with insulin (Dako #A0564) and glucagon (Cell Signaling 
Technologies #2760), AlexaFluor donkey and goat-conjugated secondary antibodies (Thermo 
Fisher), and Hoescht nuclear stain. Images were obtained at 20x on a Zeiss Confocal LSM 710 
microscope and alpha, beta, and total islet cell number for 10 islets/section were counted using 
HALO software (Indica Labs) [43], with blinding for genotypes. 
RNA extraction, reverse transcription and quantitative PCR 
Islet RNA was extracted using the Total RNA Purification Micro Kit (Norgen Biotek). 
Reverse transcription was performed using the Transcriptor First Strand cDNA Synthesis kit 
(Roche). qPCR was performed using a Roche LightCycler® 480 instrument. qPCR primers are 
listed below. Tissue-specific standard curves for each gene (primer pair) were used to convert 




36b4, Actb, and/or Gapdh expression. In cases were standard curves were not used, Cp values are 
shown, with lower Cp values indication greater mRNA expression. 
 
List of qPCR primers 
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Figure 3.1: Pdx-KO and RIP2-KO mice are glucose-intolerant. 
(A) Body weight curves of RIP2-KO and (C) Pdx-KO mice and Ildr2fl/fl controls from 8-22 weeks. 
(B) Percent fat mass of RIP2-KO mice at 17 and 22 weeks (D) Percent fat mass of Pdx-KO mice 
at 20 weeks. (E,F) Fasting glucose at 8 weeks in RIP2-KO and Pdx-KO mice. (G,H) Glucose curve 
and AUC of 8 week ipGTTs in (G) RIP2-KO or (H) Pdx-KO mice. I-J: ipGTT in 12 week RIP2-
KO and Ildr2fl/fl mice. (I) Glucose curve and AUC (J) Insulin curve and AUC (K) Insulin:glucose 
ratios (from AUC). Data are represented as mean ± standard error (SEM) * p<0.05, **p<0.01, 










Figure 3.2: HFD feeding in Pdx-KO and RIP2-KO mice. 
(A) Body weight curves of RIP2-KO mice and Ildr2fl/fl controls fed HFD from 6-28 weeks. (B) 
Body weight curves of Pdx-KO mice and Ildr2fl/fl controls fed HFD from 6-28 weeks (C,D) Blood 
glucose measurements after 4-hr fast. (E,F) Plasma insulin measurements after 4-hr fast mice at 
19 weeks. (G,H) Glucose curves and AUC of ipGTTs performed at 16 weeks. (I,J) Glucose curves 
of ipGTTs at 24 weeks old. Data are represented as mean ± standard error (SEM) * p<0.05 (Two-








Figure 3.3: Oral glucose tolerance test (OGTT) and islet glucose-stimulated insulin 
secretion (GSIS) in RIP2-KO mice 
 
Figure 3.3: Oral glucose tolerance test (OGTT) and islet glucose-stimulated insulin secretion 
(GSIS) in RIP2-KO mice  
(A) Glucose curve and AUC, (B) Insulin curve and AUC of OGTT in 10 week Ildr2fl/fl and RIP2-
KO mice. n=6-9 mice/group. (C) GSIS in Ildr2fl/fl and RIP2-KO isolated islets. Graph is ratio of 
insulin secretion at high/low glucose, normalized by islet total insulin content. Bars represent 
aggregate of 3 experiments/mouse, ~5 islet/experiment. n=3 mice/group. Data are represented as 








Figure 3.4: Islet perifusion analyses in Pdx-KO mice  
Dynamic trace of calcium signaling (A) and mitochondrial potential (B) of primary islets from 6-
8 week old Ildr2fl/fl and Pdx-KO mice in response to 14 mM glucose for 20 min and 30 mM KCI 
for 15 min. Average values from 3 mice, ~50 islets/mouse. (C) Dynamic insulin secretion 
measured in the same experiment as (A) and (B), less one Pdx-KO sample. (D) Area under the 










Figure 3.5: Islet cell quantification in RIP2-KO and Pdx-KO mice 
A-C,G: Representative immunofluorescent images of pancreatic islets from (A) 23-29 week 
Ildr2fl/fl and RIP2-KO mice, (G) 24 week Ildr2fl/fl and Pdx-KO mice. (B) Percent insulin-positive 
area and (C) number of islets quantified by non-fluorescent immunohistochemistry in 23-29 week 
Ildr2fl/fl and RIP2-KO mice, 6 pancreatic sections per mouse. D-F,H-J: Quantification of 
immunofluorescent staining of 3 pancreas sections per mouse, 200-300 μm apart. ~10 islets/section 
were quantified. (D) Total cell number, (E) beta cell number, and (F) alpha cell number in 23-29 
week Ildr2fl/fl and RIP2-KO mice. (H) Total cell number, (I) beta cell number, and (J) alpha cell 
number in 24 week Ildr2fl/fl and Pdx-KO mice. n=3 mice/genotype for all experiments. Data are 

























Figure 3.6: Ildr2 expression in islets and hypothalamic of RIP2- KO and Pdx-KO islets 
Islets: qPCR expression of (A) Ildr2-isoform 1, (B) exon 1 of Ildr2, and (C) Cre in 10-24 week 
Ildr2fl/fl control and RIP2-KO mice. (D) qPCR expression in 24 week control and Pdx-KO mice of 
Ildr2-isoform 1, (E) exon 1 of Ildr2, and (F) Cre. Hypothalamus qPCR expression: (G) Ildr2-
isoform 1 and (H) Cre in Ildr2fl/fl control and RIP2-KO mice. (I) Ildr2-isoform 1 and (J) Cre 
expression in control and Pdx-KO mice. For exon 1 and Cre, expression is shown as Cp (threshold 
crossing point) values. Lower Cp values indicate higher expression and vice versa. n=4-10 mice 




Figure 3.7: hGH and Tph1 expression in RIP2-KO, Pdx-KO, and WT islets 
 
 
Figure 3.7: hGH and Tph1 expression in RIP2-KO, Pdx-KO, and WT islets 
Islet qPCR expression of (A) hGH and (B) Tph1 in RIP2-KO, Pdx-KO, littermate controls, and 
WT (B6) mice. hGH expression is shown as Cp values; Tph1 expression is normalized to 36b4, 




Table 3.1: Summary of phenotypes in RIP2-KO and Pdx-KO mice 
Experimental assay RIP2-KO mice Pdx-KO mice 
Islet expression Retain Ildr2 expression; 
express hGH 
Complete Ildr2 KO; 
No hGH expression 
HFD feeding Decreased body weight, 
fasting glucose, and insulin 
No difference in body weight, 
glucose or insulin 
Intraperitoneal GTT Impaired glucose tolerance Impaired glucose tolerance 
Oral GTT Impaired glucose tolerance 
and decreased insulin 
secretion 
-- 
GSIS Increased insulin secretion -- 
Islet perifusion -- Reduced insulin secretion, 
decreased calcium signaling 
Islet morphology Increased islet size and beta 
cell number 
No difference in islet size and 






















1. Bonnefond, A., P. Froguel, and M. Vaxillaire, The emerging genetics of type 2 diabetes. 
Trends in Molecular Medicine, 2010. 16(9): p. 407-416. 
2. Zeggini, E., et al., Meta-analysis of genome-wide association data and large-scale 
replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet, 2008. 
40(5): p. 638-645. 
3. Voight, B.F., et al., Twelve type 2 diabetes susceptibility loci identified through large-
scale association analysis. Nat Genet, 2010. 42(7): p. 579-589. 
4. Dokmanovic-Chouinard, M., et al., Positional cloning of "Lisch-Like", a candidate 
modifier of susceptibility to type 2 diabetes in mice. PLoS Genet, 2008. 4(7): p. 
e1000137. 
5. Postic, C., et al., Dual Roles for Glucokinase in Glucose Homeostasis as Determined by 
Liver and Pancreatic β Cell-specific Gene Knock-outs Using Cre Recombinase. Journal 
of Biological Chemistry, 1999. 274(1): p. 305-315. 
6. Lee, J.-Y., et al., RIP-Cre Revisited, Evidence for Impairments of Pancreatic β-Cell 
Function. Journal of Biological Chemistry, 2006. 281(5): p. 2649-2653. 
7. Pomplun, D., et al., Alterations of Pancreatic Beta-cell Mass and Islet Number due to 
Ins2-controlled Expression of Cre Recombinase: RIP-Cre Revisited; Part 2. Horm Metab 
Res, 2007. 39(05): p. 336-340. 
8. Hingorani, S.R., et al., Preinvasive and invasive ductal pancreatic cancer and its early 
detection in the mouse. Cancer Cell, 2003. 4(6): p. 437-450. 
9. Mastracci, T.L., et al., Nkx2.2 and Arx genetically interact to regulate pancreatic 
endocrine cell development and endocrine hormone expression. Developmental Biology, 
2011. 359(1): p. 1-11. 
10. Zhang, J., et al., Disruption of Growth Factor Receptor–Binding Protein 10 in the 
Pancreas Enhances β-Cell Proliferation and Protects Mice From Streptozotocin-Induced 
β-Cell Apoptosis. Diabetes, 2012. 61(12): p. 3189-3198. 
11. Hanlon, L., et al., Notch1 Functions as a Tumor Suppressor in a Model of K-ras–Induced 
Pancreatic Ductal Adenocarcinoma. Cancer Research, 2010. 70(11): p. 4280-4286. 
12. Seeley, E.S., et al., Pancreatic Cancer and Precursor Pancreatic Intraepithelial 





13. Gannon, M., et al., Analysis of the Cre-mediated recombination driven by rat insulin 
promoter in embryonic and adult mouse pancreas. genesis, 2000. 26(2): p. 139-142. 
14. Lin, X., et al., Dysregulation of insulin receptor substrate 2 in β cells and brain causes 
obesity and diabetes. The Journal of Clinical Investigation, 2004. 114(7): p. 908-916. 
15. Cui, Y., et al., Essential Role of STAT3 in Body Weight and Glucose Homeostasis. 
Molecular and Cellular Biology, 2004. 24(1): p. 258-269. 
16. Nguyen, K.-T.T., et al., Essential Role of Pten in Body Size Determination and 
Pancreatic β-Cell Homeostasis In Vivo. Molecular and Cellular Biology, 2006. 26(12): p. 
4511-4518. 
17. Fex, M., et al., Rat insulin promoter 2-Cre recombinase mice bred onto a pure C57BL/6J 
background exhibit unaltered glucose tolerance. Journal of Endocrinology, 2007. 194(3): 
p. 551-555. 
18. Koch, G.L.E., The endoplasmic reticulum and calcium storage. BioEssays, 1990. 12(11): 
p. 527-531. 
19. Berridge, M.J., The endoplasmic reticulum: a multifunctional signaling organelle. Cell 
Calcium, 2002. 32(5): p. 235-249. 
20. Worley, J.F., et al., Endoplasmic reticulum calcium store regulates membrane potential 
in mouse islet beta-cells. Journal of Biological Chemistry, 1994. 269(20): p. 14359-
14362. 
21. Brissova, M., et al., Pancreatic Islet Production of Vascular Endothelial Growth Factor-
A Is Essential for Islet Vascularization, Revascularization, and Function. Diabetes, 2006. 
55(11): p. 2974-2985. 
22. Wicksteed, B., et al., Conditional Gene Targeting in Mouse Pancreatic β-Cells. Analysis 
of Ectopic Cre Transgene Expression in the Brain, 2010. 59(12): p. 3090-3098. 
23. Benner, C., et al., The transcriptional landscape of mouse beta cells compared to human 
beta cells reveals notable species differences in long non-coding RNA and protein-coding 
gene expression. BMC Genomics, 2014. 15(1): p. 1-17. 
24. Banaei-Bouchareb, L., et al., A transient microenvironment loaded mainly with 
macrophages in the early developing human pancreas. Journal of Endocrinology, 2006. 
188(3): p. 467-480. 
25. Criscimanna, A., et al., Activated Macrophages Create Lineage-Specific 
Microenvironments for Pancreatic Acinar- and β-Cell Regeneration in Mice. 
Gastroenterology, 2014. 147(5): p. 1106-1118.e11. 
26. Ehses, J.A., et al., Increased Number of Islet-Associated Macrophages in Type 2 




27. Westwell-Roper, C.Y., J.A. Ehses, and C.B. Verchere, Resident Macrophages Mediate 
Islet Amyloid Polypeptide–Induced Islet IL-1β Production and β-Cell Dysfunction. 
Diabetes, 2014. 63(5): p. 1698-1711. 
28. Xu, X., et al., Obesity Activates a Program of Lysosomal-Dependent Lipid Metabolism in 
Adipose Tissue Macrophages Independently of Classic Activation. Cell Metabolism, 
2013. 18(6): p. 816-830. 
29. Brouwers, B., et al., Impaired Islet Function in Commonly Used Transgenic Mouse Lines 
due to Human Growth Hormone Minigene Expression. Cell Metabolism, 2014. 20(6): p. 
979-990. 
30. Parsons, J.A., A. Bartke, and R.L. Sorenson, Number and size of islets of Langerhans in 
pregnant, human growth hormone-expressing transgenic, and pituitary dwarf mice: effect 
of lactogenic hormones. Endocrinology, 1995. 136(5): p. 2013-2021. 
31. Huang, C., F. Snider, and J.C. Cross, Prolactin Receptor Is Required for Normal Glucose 
Homeostasis and Modulation of β-Cell Mass during Pregnancy. Endocrinology, 2009. 
150(4): p. 1618-1626. 
32. Green, I.C. and K.W. Taylor, Effects of pregnancy in the rat on the size and insulin 
secretory response of the islets of Langerhans. Journal of Endocrinology, 1972. 54(2): p. 
317-325. 
33. Schraenen, A., et al., Placental lactogens induce serotonin biosynthesis in a subset of 
mouse beta cells during pregnancy. Diabetologia, 2010. 53(12): p. 2589-2599. 
34. Kim, H., et al., Serotonin regulates pancreatic beta cell mass during pregnancy. Nat 
Med, 2010. 16(7): p. 804-808. 
35. Ravier, M.A., et al., Mechanisms of Control of the Free Ca2+ Concentration in the 
Endoplasmic Reticulum of Mouse Pancreatic β-Cells: Interplay With Cell Metabolism 
and [Ca2+]c and Role of SERCA2b and SERCA3. Diabetes 2011. 60(10): p. 2533-2545. 
36. Wang, R., et al., Insulin Secretion and Ca2+ Dynamics in β-Cells Are Regulated by PERK 
(EIF2AK3) in Concert with Calcineurin. The Journal of Biological Chemistry, 2013. 
288(47): p. 33824-33836. 
37. Soria, B., et al., Pancreatic islet cells: a model for calcium-dependent peptide release. 
HFSP Journal, 2010. 4(2): p. 52-60. 
38. Chao, S.-H., et al., PDX1, a Cellular Homeoprotein, Binds to and Regulates the Activity 
of Human Cytomegalovirus Immediate Early Promoter. Journal of Biological Chemistry, 
2004. 279(16): p. 16111-16120. 
39. Halldorsdottir, S., et al., Reproducibility and accuracy of body composition assessments 
in mice by dual energy x-ray absorptiometry and time domain nuclear magnetic 




40. Zmuda, E.J., C.A. Powell, and T. Hai, A Method for Murine Islet Isolation and 
Subcapsular Kidney Transplantation. Journal of Visualized Experiments : JoVE, 
2011(50): p. 2096. 
41. Wang, H., et al., The Transcription Factor SREBP-1c Is Instrumental in the Development 
of β-Cell Dysfunction. Journal of Biological Chemistry, 2003. 278(19): p. 16622-16629. 
42. Adewola, A.F., et al., Microfluidic perifusion and imaging device for multi-parametric 
islet function assessment. Biomed Microdevices, 2010. 12(3): p. 409-17. 
43. Morabito, M.V., et al., Weight Perturbation Alters Leptin Signal Transduction in a 






















This thesis describes efforts to characterize the function of Ildr2, a gene predicted by 
positional genetics to be a modifier of diabetes susceptibility [1], and implicated by knockdown 
studies in hepatic lipid metabolism and fatty liver disease [2]. Investigations of the molecular 
functions of ILDR2 have suggested that it is regulated by ER stress transducers, binds ApoE, and 
may negatively regulate components of the Notch signaling pathway [3]. However, the precise 
molecular bases for the physiological roles of   ILDR2 have yet to be determined.  
One of the obstacles to investigating the functions of ILDR2 has been the lack of precise 
Ildr2 KO mouse models. Thus, our previous studies of ILDR2 were limited to hypomorphic 
congenic, mutagenized, or virus-infected mouse models, and molecular targeting in vitro. The 
recent development of a conditional Ildr2 floxed mouse has facilitated further understanding of 
the role of ILDR2. The overall focus of my work has been to characterize tissue-specific Ildr2 KO 
mice, defining the function of ILDR2 in different tissues. Using these mice, I have confirmed that 
ILDR2 plays a role in pancreas endocrine function, but disproved the hypothesis that ILDR2 is 
essential for hepatic lipid homeostasis. 
 
PART I: Overview of ILDR2 in the liver 
 In Chapter 2, I describe the generation of congenital hepatocyte-specific, Ildr2 KO mice. 
In these animals I found that, contrary to prior expectations based on studies of adenoviral shRNA-
mediated Ildr2 KD (ADKD) mice, they did not develop hepatic steatosis. Hypothesizing that this 
lack of phenotype could be due to developmental compensation for early loss of Ildr2 expression, 
we developed acute, whole-liver (vs. hepatocyte-only) Ildr2 KO mice.  However, these animals 




metabolic stress conveyed by high-fat diet (HFD) triggered hepatic lipid dysregulation in 
hepatocyte-specific, Ildr2 KO mice. We concluded that the adenoviral shRNA used to knockdown 
Ildr2 in prior studies must have had off-target effects which could account for the hepatic steatosis 
apparent in ADKD mice. This inference was confirmed in Ildr2 liver KO mice infected with the 
original Ildr2-shRNA adenovirus. Ildr2 liver KO mice administered the adenoviral shRNA 
accumulated excess liver triglycerides, despite the absence of Ildr2 expression before or after 
infection.  
To identify the gene(s) inadvertently targeted by the Ildr2-shRNA, and potentially 
responsible for causing fatty liver disease in ADKD mice, we performed RNA sequencing on 
ADKD and Ildr2 liver KO mouse livers. 102 candidate genes were selected using the following 
parameters (See Table 2.2):  
(1) Significantly decreased expression in ADKD vs. AD-lacZ controls,   
(2) Significantly decreased expression in ADKD vs. Ildr2 liver KO samples, and 
(3) No significant difference in expression between AD-lacZ controls and Ildr2 liver KOs.  
Because genes meeting these criteria could be decreased by secondary effects of shRNA rather 
than by direct targeting, BLAST searches were performed to identify genes bearing sequence 
similarity to Ildr2 shRNA. Dgka was the only gene of 102 candidates found to match a portion of 
the shRNA sequence. Dgka encodes diacylglyceride kinase alpha (DGKα) which regulates cellular 
signaling by converting diacylglyceride to phosphatidic acid. Dgka-/- mice have been created to 
understand the role of DGKα in immune signaling and T-cell anergy [4]. Hepatic phenotypes of 
these mice have not been reported, and inhibitors of Dgka designed to stimulate immune responses 
to cancer are thought have no side effects [5]. However, embryonic fibroblasts cultured from Dgka-




these mice develop hepatic steatosis. Future work will include characterizing Dgka-/- mice for 
hepatic lipid accumulation.  
ADKD mice can be thought of as a “double KD” model since the shRNA potentially 
targeted both Ildr2 and Dgka. Although not sufficient to cause hepatic steatosis, reduction of 
ILDR2 may have contributed to the lipid phenotypes in ADKD mice. To test this hypothesis, we 
will develop Dgka/Ildr2 double KO mice and observe their susceptibility to hepatic steatosis. 
Additionally, ILDR2 has been shown to bind ApoE, which is consistent with a potential role in 
lipid transport and metabolism. Thus our work does not necessarily eliminate, but rather minimizes 
the putative function of ILDR2 in maintaining hepatic lipid metabolism. 
 
Significance of Ildr2 overexpression 
Our original studies with ADKD mice also demonstrated that Ildr2 overexpression greatly 
reduces lipid accumulation in the case of pre-existing steatosis (i.e. Lepob/ob mice) [2]; this effect 
could have significant therapeutic applications. Confirming that Ildr2 KD does not cause hepatic 
steatosis does not negate a functional impact of Ildr2 overexpression on hepatic lipid content. It is 
quite plausible that the effects of Ildr2 KD vs. Ildr2 overexpression are related but not reciprocal. 
As reviewed in Chapter 1, additional experiments showed that Ildr2 overexpression did not rescue 
hepatic steatosis in high-fat, high-fructose fed mice, which exhibited liver fibrosis in addition to 
lipid accumulation. Further study is required to confirm the effects of Ildr2 overexpression in 
steatotic mice. Overexpression studies are necessarily problematic not only because they often 
utilize transiently-expressed molecular vehicles (in our case, adenovirus), but also because they 
can result in supra-physiological levels of expression which are not representative of normal 




critical when investigating the therapeutic utility of upregulating gene expression. However, to 
avoid the confounding effects of adenovirus treatment, gain-of-function conditional transgenic 
constructs will be the best option for further study. 
 
PART II: Overview of ILDR2 in the pancreas 
 In Chapter 3 we described the phenotype of pancreas-specific (Pdx-Cre) Ildr2 KO mice 
and confirmed that they exhibited phenotypes consistent with those observed in the B6.DBA 
Chr.1q23 congenic Ildr2 hypomorphic (congenic) mice. Pdx-KO mice displayed impaired glucose 
tolerance, and both reduced insulin secretion and decreased calcium signaling in isolated islets, 
suggesting that Ildr2 plays a role in glucose sensing and insulin secretion in beta cells. We also 
assessed diabetic phenotypes of beta cell-specific (RIP2-cre) Ildr2 KO mice and observed 
impaired glucose tolerance, reduced insulin secretion in vivo, but increased insulin secretion ex 
vivo, and beta cell hyperplasia. However, the expression of human growth hormone (hGH) in 
RIP2-KO mice confounds these results. Because the RIP2-Cre construct, in isolation, has been 
shown to trigger these same phenotypes as a result of hGH expression, we cannot with certainty 
attribute them to loss of Ildr2 in the beta cell. Since the controls used in our experiments were 
Ildr2 floxed mice, rather than RIP2-Cre mice, we cannot certify the specificity of ILDR2 function 
in the RIP2-KO mice.  
 Additionally, islet expression analyses showed that Ildr2 was knocked out in Pdx-KO 
islets, but not in RIP2-KO islets, indicating that Ildr2 is expressed in islet cells other than beta 
cells. Thus, despite potential phenotypic confounding of the RIP2-KO mice, comparison of these 
two mouse models led us to consider Ildr2 expression in alternative islet cell types. After 




adipose tissue macrophages [8], we hypothesized that Ildr2 may be expressed in islet macrophages 
at higher levels than in endocrine cells, and that the genes effects on islet function may be conveyed 
through this cell type. 
 
Proposed function of ILDR2 in islet macrophages 
Apart from their evident role in the development of autoimmune (Type 1) diabetes, islet 
macrophages have been primarily described as activators of beta cell proliferation and regeneration 
[9, 10]. Interestingly, congenic mice exhibited reduced beta cell mass due to decreased 
proliferation [1], thus if Ildr2 is expressed in islet macrophages it might play a role in the 
proliferative function of these cells. Pdx-KO mice fed low-fat chow showed no difference in beta 
cell number compared to controls at 24 weeks, implying that they do not have a proliferative defect. 
A reduction in proliferation may be more apparent in HFD-fed Pdx-KO mice, as beta cell 
proliferation is stimulated in the context of insulin resistance [11]. Recall that Ildr2 was cloned 
based on the diabetes phenotypes of Lepob/ob mice.  Additionally, we can examine beta cell 
proliferation in the peak perinatal window of islet development. These further investigations will 
determine if beta cell proliferation is affected in Pdx-KO mice. 
 
ILDR2 and islet cell calcium signaling 
The in vivo and in vitro phenotypes of Pdx-KO islets suggest that loss of Ildr2 in cells of 
the islet (possibly the macrophage) leads to reduced calcium signaling and decreased insulin 
secretion by the beta cell, resulting in glucose intolerance. Insulin secretion is stimulated by a 
precise series of events starting with glucose sensing by the beta cell receptor, GLUT2, 




the cell membrane causing calcium channels to open, upon which calcium ions diffuse into the 
cell and stimulate insulin granule secretion [12]. Mitochondrial potential was unchanged between 
Pdx-KO and control islets (Fig. 3.4B), implying that the defect caused by Ildr2 KO is downstream 
of ATP production.  
Since insulin secretion is dependent on voltage-gated calcium flux across the cell 
membrane, ion concentrations must be tightly regulated within the cell. The endoplasmic reticulum 
is the major calcium storage organelle with associated calcium regulatory proteins [13]. We 
hypothesize that ILDR2 in the ER membrane plays a role in maintaining cellular calcium 
concentrations, and that Ildr2 KO in islets alters the calcium concentration gradient, impairing 
calcium channel signaling with detrimental effects for insulin secretion. Glucagon and 
somatostatin secretion also involve calcium signaling [14-16], thus loss of Ildr2 in Pdx-KO mice 
may also affect alpha and delta cell function.  
This proposed role for ILDR2 in calcium regulation is reminiscent of 2D polyacrylamide 
gel electrophoresis studies of hypothalamic and liver tissue of W87* mice (Chapter 1) in which 
amounts of several calcium-related signaling molecules (e.g. calbindin D, neurocalcin, visinin-like 
protein 3) were decreased. However, the persistence of Ildr2 expression in W87* mice renders it 
doubtful that these changes were reflective of loss of ILDR2 function.   
 
Future work on the role of ILDR2 in the pancreas 
These studies of the function of ILDR2 in the pancreas are a work in progress. Our next 
step is to determine which cells in the pancreatic islet express Ildr2. We will start by isolating 
macrophage and beta cell populations by cell sorting to measure Ildr2 expression in separate 




islets, despite testing several antibodies. Thus, we will need to perform in situ hybridization to 
determine exactly which islet cells express Ildr2. Probing additional pancreatic islet single-cell 
sequencing results will also help define the expression pattern of Ildr2. While we and others have 
shown that Ildr2 is expressed at low levels in islet endocrine cells [7], this may not denote 
functional irrelevance. Recently, subsets of lowly-expressed “disallowed” genes have been 
identified in alpha and beta cells which play a role in cell proliferation, but are transcriptionally 
repressed to limit growth of mature beta cells [17]. Ildr2 could be similarly regulated, relating to 
its putative function in beta cell proliferation. 
To understand how islet morphology may be affected in Pdx-KO mice, we will quantify 
islet cell number and macrophages by immunohistochemistry, and measure beta proliferation by 
Ki67 or Brdu immunostaining. We will also measure mRNA expression of known calcium 
regulatory proteins in Pdx-KO beta cells, perform patch-clamping studies on beta cell to better 
understand changes in ion channel function, and identify putative calcium binding domains in 
ILDR2 to further explore its role in islet cell calcium signaling mechanisms. To determine if 
calcium-stimulated secretion is affected by Ildr2 KO in alpha and delta cells, we will measure 
glucagon and somatostatin secretion in Pdx-KO mice. Finally, RNAseq of whole islets, isolated 
beta cells, and/or islet macrophages could be used to identify genes differentially regulated in Pdx-
KO mice and understand which mechanistic pathways are affected. Additionally, we have an 
ongoing collaboration with Dr. George Gittes at the University of Pittsburgh to infuse AAV-RIP-
Cre [18] directly into the pancreata of Ildr2 floxed mice, allowing for beta cell-specific, acute Ildr2 






PART III: Additional proposed functions of ILDR2 
ILDR2 in the brain 
Ildr2 is more highly expressed in the brain than in any other tissue, suggesting a functional 
role in centrally-regulated metabolism. ILDR2 could be involved in the hypothalamic regulation 
of insulin secretion by various mechanisms such as, neuronal glucose sensing [19] or the 
melanocortin system [20]. Interestingly, the ectopic expression of RIP2-cre in the hypothalamus 
[21, 22] has helped establish critical roles for several hypothalamus-expressed genes hypothalamic 
regulation of metabolism and beta cell function, most notably Irs2 [23-25], but also Stat3 [26] and 
Pten [27]. Persistence of Ildr2 expression in the hypothalami of RIP2-KO and Pdx-KO mice 
(Fig.3.6G-J) confirmed that floxed Ildr2 alleles in the hypothalamus were not affected by RIP2-
cre or Pdx-cre expressing hypothalamic neurons. However, since these Cre-expressing neurons are 
a poorly-defined subgroup distributed throughout the hypothalamus [22, 28, 29], this finding does 
not enable definitive conclusions regarding a role for ILDR2 in hypothalamic regulation of beta 
cell function. 
The interaction between ILDR2 and ApoE could also be related to ILDR2’s putative brain 
function. ApoE ε4, the major risk allele for Alzheimer’s disease, is thought to be a hypomorphic 
allele; thus protective functions have been identified for ApoE in the brain. ILDR2 may participate 
with  ApoE in its functional roles of neuronal lipid transport and clearance of amyloid beta proteins 
[30]. However, since the ApoE binding sites for ILDR2 and amyloid beta are overlapping, ILDR2 
could also have the negative effect of sequestering ApoE, possibly leading to amyloid beta 






Proposed role of leptin in ILDR2 biology 
Two of the most interesting phenotypes observed in  Ildr2 functional studies – 
hypoinsulinemic hyperglycemia due to reduced beta cell mass in congenic mice [1], and 
amelioration of hepatic steatosis by Ildr2 overexpression [2] – were observed in Lepob/ob mice. 
Neither of these phenotypes has been replicated in leptin-expressing mice, suggesting that ILDR2 
effects may be context-dependent with regard to leptin sufficiency. 
Potential mechanisms for such an interaction are informed by direct leptin action on the 
beta cell [31] whereby it inhibits insulin gene expression and secretion by various mechanisms, 
including activation of potassium channels in the beta cell [32-35]. However, insulin secretion is 
reduced in Ildr2-deficient mice which rather suggests that leptin and ILDR2 have opposing roles 
in modulating beta cell function. Alternatively, since the primary function of leptin is hypothalamic 
regulation of feeding behavior and body weight, ILDR2 could function in the brain downstream 
of leptin signaling. 
 
Contribution of extra-pancreatic Ildr2 deficiency to original diabetic phenotypes 
An additional point to consider in comparing congenic mice with Pdx-KO mice is that 
congenics were Ildr2 deficient in every tissue; they were not organ or cell type-specific KOs. Ildr2 
is ubiquitously expressed and, in several tissues, at higher levels than in pancreatic islets. Thus, it 
very plausible that loss of Ildr2 in related metabolic tissues; such as liver, adipose tissue, and 








To explore the above-mentioned hypotheses about Ildr2 cross-tissue regulation, as well as 
investigate the role of ILDR2 in the brain, we have generated whole-body Ildr2 KO mice and 
confirmed complete Ildr2 ablation in a range of organs (Fig. 4.1A). KO mice are viable and fertile, 
and have no obvious developmental or metabolic defects. However, upon HFD feeding, KO mice 
preferentially gain fat mass despite no significant difference in body weight from WT controls 
(Fig. 4.1B,D,E). This increase in fat mass is apparently not due to hyperphagia (Fig. 4.1C), 
suggesting that KO mice may have decreased energy expenditure.  
Future work in these mice will focus on measurements of energy expenditure as well as 
assessing changes in hypothalamic leptin signaling. These preliminary results specify a role for 
ILDR2 in body mass determination and support the hypothesis that ILDR2 is involved in 
hypothalamic regulation of metabolism.  
 
CONCLUSIONS  
The contributions of this thesis work to metabolic research in general, and to the study of 
ILDR2 in particular, are three-fold. First, the discovery that Ildr2 ablation is not responsible for a 
phenotype of massive hepatic steatosis led us to identify novel candidate regulators of hepatic lipid 
homeostasis, which will enable new mechanisms of lipid accumulation in fatty liver disease to be 
identified. Second, the diabetic phenotypes described in pancreas Ildr2 KO mice provide the very 
first confirmation of the role of ILDR2 as a modifier of diabetes susceptibility. Further 
investigation into the mechanism of ILDR2 will lead to a better understanding of the role of ILDR2 




will facilitate investigation into additional functions of ILDR2, e.g. as a component of tricellular 
tight junctions, or in metabolic partitioning of energy stores. 
 







Figure 4.1: Whole-body Ildr2 KO mice have increased fat mass on HFD 
Ildr2 floxed mice were crossed with mice expressing Cre driven by the CMV promoter to produce 
whole-body Ildr2 KO mice. (A) Ildr2-isoform 1 expression (log scale) in tissues from WT and KO 
mice in decreasing order of Ildr2 expression, n=2. Gene expression was measured by qPCR and 
normalized to beta actin expression. >90% reduction in Ildr2 expression was detected in each 
tissue. (B) Body weight of WT, KO and heterozygous (Het) male mice measured 2x/weekly from 
3.5-14.5 weeks old. Mice were HFD-fed from 6 weeks old (indicated by arrows). (C) Food intake 
measured 2x/weekly from 4-14.5 weeks old. Mice were housed 2-3/cage, n=3 cages/genotype. (D) 
Fat mass measured weekly from 4-14 weeks old. (E) Lean mass measured weekly from 4-14 weeks 
old. Data are represented as mean ± standard error (SEM). ** p<0.01 for KO vs. WT (Two-way 
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